Preview
Full Doc
 | 2002 |
Network Alliance Agreement
Network Alliance Agreement (106K)
Doc #128951: Click preview link for longer preview.
NETWORK ALLIANCE AGREEMENT
BETWEEN
FLAG TELECOM IRELAND NETWORK LIMITED
AND
VERIZON GLOBAL SOLUTIONS HOLDINGS II LTD.
{Page}
NETWORK ALLIANCE AGREEMENT
This Network Alliance Agreement ("AGREEMENT") is entered into as of April 3, 2001, between FLAG Telecom Ireland Network Limited ("FTINL" and, together with FLAG Telecom Holdings Limited and all directly or indirectly wholly-owned subsidiaries of FLAG Telecom Holdings Limited, and any other Affiliates (as defined below) added pursuant to Section 1.2 below, "FLAG"), a company limited by shares organized under the laws of Ireland with its registered office located at 6 Fitzwilliam Square, Dublin 2, Ireland, and Verizon Global Solutions Holdings II Ltd. ("VGSL" and, together with its Affiliates, "VGS"), a company organized under the laws of Bermuda with its registered office located at 41 Cedar Avenue, Hamilton HM 12, Bermuda. Hereinafter, FTINL and VGSL may be referred to together as "PARTIES", and individually as a "PARTY".
WHEREAS:
A. VGS wishes to establish, own and operate a European backbone network (the "VGSIEN") with sufficient capacity and geographic scope to enable both VGS (and its Affiliates) and FLAG to provide end-to-end provisioning of network services to their respective customers and to market such service offerings under their separate, proprietary brands.
B. FLAG has spent considerable time in the planning of extensions to its existing network.
C. VGS and FLAG desire to create a network alliance to participate in the establishment and use of the VGSIEN (the "ALLIANCE"). The initial scope of the VGSIEN is that set out in Exhibit C and may be expanded in accordance with the terms of this Agreement.
D. As part of the Alliance, VGS desires to provide transport and related telecommunications services to FLAG to support the services that FLAG offers to their customers.
In consideration of the premises recited above and of the mutual promises and undertakings set forth in this Agreement, and intending to be legally bound, the Parties hereby agree as follows:
{Page}
1. SERVICES; FORECASTS; SERVICE ORDERS
1.1 The services which VGS will make available through the VGSIEN (the "SERVICES") are set forth in Exhibit B hereto, which is incorporated by reference and which may be amended from time to time in order to add additional Services by mutual agreement of the Parties.
1.2 VGS shall provide Services under the terms of this Agreement to FLAG Telecom Holdings Limited and any directly or indirectly wholly owned subsidiary of FLAG Telecom Holdings Limited, as well as to such other Affiliates of FTINL as FTINL may request, and VGSL in its sole discretion shall agree to in writing. VGSL may provide the Services through one or more operating Affiliates. As used herein, an "AFFILIATE" of any company shall mean another company which controls, is controlled by, or is under common control with such company. FTINL shall be responsible for all orders placed by any member of FLAG, and shall be liable to VGSL for all amounts due hereunder with respect to any Services provided to any member of FLAG as well as for performance by all members of FLAG of all of their respective obligations hereunder. FTINL shall be bound by any action taken pursuant to or in connection with this Agreement by any member of FLAG. VGSL shall be responsible for all Services provided by any member of VGS. VGSL shall be bound by any action taken pursuant to or in connection with this Agreement by any member of VGS. The Purchase Commitments (as defined in Section 1.4) shall be determined on an aggregate basis for FLAG, and any Service provided to any member of FLAG shall be counted toward the applicable Purchase Commitment for such order, with VGSL having no responsibility to allocate such Purchase Commitment among the members of FLAG except as provided in Section 3. FLAG may purchase and use the Services only for purposes of providing bundled end-to-end services to end-users, and are strictly prohibited from reselling any Service unless bundled with other products or services provided by FLAG or other suppliers.
128951
|
Verizon
As referenced in this Network Alliance Agreement:
Verizon Communications – this Agreement upon 30 days written notice
to the other in the event that (i) Verizon Communications Inc. and its
controlled affiliates shall own, in the aggregate, less than 9% of Verizon Communications – appointed or elected by any person, or group of
persons acting in concert, other than Verizon Communications Inc. and
its controlled affiliates, or (iii) FLAG Telecom Holdings Limited
shall have sold Verizon Communications – significant portion thereof to any person, or group of persons
acting in concert, other than Verizon Communications Inc. and its
controlled affiliates. Notwithstanding a termination pursuant to this
Section 5.7,
dt 39360
;
Flag Telecom Ireland Network Limited;
| Verizon Global Solutions Holdings II Ltd.;
Flag Telecom Group Ltd.
|
Preview
Full Doc
 | 2001 |
Network Alliance Agreement
Network Alliance Agreement (96K)
Doc #129080: Click preview link for longer preview.
NETWORK ALLIANCE AGREEMENT
This Network Alliance Agreement ("AGREEMENT") is entered into as of April 3, 2001, between FLAG Telecom Ireland Network Limited ("FTINL" and, together with FLAG Telecom Holdings Limited and all directly or indirectly wholly-owned subsidiaries of FLAG Telecom Holdings Limited, and any other Affiliates (as defined below) added pursuant to Section 1.2 below, "FLAG"), a company limited by shares organized under the laws of Ireland with its registered office located at 6 Fitzwilliam Square, Dublin 2, Ireland, and Verizon Global Solutions Holdings II Ltd. ("VGSL" and, together with its Affiliates, "VGS"), a company organized under the laws of Bermuda with its registered office located at 41 Cedar Avenue, Hamilton HM 12, Bermuda. Hereinafter, FTINL and VGSL may be referred to together as "PARTIES", and individually as a "PARTY".
WHEREAS:
A. VGS wishes to establish, own and operate a European backbone network (the "VGSIEN") with sufficient capacity and geographic scope to enable both VGS (and its Affiliates) and FLAG to provide end-to-end provisioning of network services to their respective customers and to market such service offerings under their separate, proprietary brands.
B. FLAG has spent considerable time in the planning of extensions to its existing network.
C. VGS and FLAG desire to create a network alliance to participate in the establishment and use of the VGSIEN (the "ALLIANCE"). The initial scope of the VGSIEN is that set out in Exhibit C and may be expanded in accordance with the terms of this Agreement.
D. As part of the Alliance, VGS desires to provide transport and related telecommunications services to FLAG to support the services that FLAG offers to their customers.
{Page}
In consideration of the premises recited above and of the mutual promises and undertakings set forth in this Agreement, and intending to be legally bound, the Parties hereby agree as follows:
1. SERVICES; FORECASTS; SERVICE ORDERS -----------------------------------
1.1 The services which VGS will make available through the VGSIEN (the "SERVICES") are set forth in Exhibit B hereto, which is incorporated by reference and which may be amended from time to time in order to add additional Services by mutual agreement of the Parties.
1.2 VGS shall provide Services under the terms of this Agreement to FLAG Telecom Holdings Limited and any directly or indirectly wholly owned subsidiary of FLAG Telecom Holdings Limited, as well as to such other Affiliates of FTINL as FTINL may request, and VGSL in its sole discretion shall agree to in writing. VGSL may provide the Services through one or more operating Affiliates. As used herein, an "AFFILIATE" of any company shall mean another company which controls, is controlled by, or is under common control with such company. FTINL shall be responsible for all orders placed by any member of FLAG, and shall be liable to VGSL for all amounts due hereunder with respect to any Services provided to any member of FLAG as well as for performance by all members of FLAG of all of their respective obligations hereunder. FTINL shall be bound by any action taken pursuant to or in connection with this Agreement by any member of FLAG. VGSL shall be responsible for all Services provided by any member of VGS. VGSL shall be bound by any action taken pursuant to or in connection with this Agreement by any member of VGS. The Purchase Commitments (as defined in Section 1.4) shall be determined on an aggregate basis for FLAG, and any Service provided to any member of FLAG shall be counted toward the applicable Purchase Commitment for such order, with VGSL having no responsibility to allocate such Purchase Commitment among the members of FLAG except as provided in Section 3. FLAG may purchase and use the Services only for
129080
|
Verizon
As referenced in this Network Alliance Agreement:
Verizon Communications – this Agreement upon 30 days written
notice to the other in the event that (i) Verizon Communications
Inc. and its controlled affiliates shall own, in the aggregate, less
than 9% of Verizon Communications – appointed or elected by any person, or group of persons
acting in concert, other than Verizon Communications Inc. and its
controlled affiliates, or (iii) FLAG Telecom Holdings Limited shall
have sold Verizon Communications – significant portion thereof to any person, or group of persons
acting in concert, other than Verizon Communications Inc. and its
controlled affiliates. Notwithstanding a termination pursuant to
this Section 5.7,
dt 39361
;
FLAG Telecom Ireland Network Limited;
| Verizon Global Solutions Holdings II Ltd.;
Flag Telecom Group Ltd
|
Preview
Full Doc
 | 2003 |
Strategic Alliance Agreement
Strategic Alliance Agreement (98K)
Doc #141673: Click preview link for longer preview.
STRATEGIC ALLIANCE AGREEMENT
This Agreement ("Agreement") is effective as of October 15, 2002 ("Effective Date") by and between ZiLOG, Inc., a Delaware corporation having a place of business at 532 Race Street, San Jose, CA 95126 ("ZiLOG"), and USA Technologies, Inc., a Pennsylvania corporation having a place of business at 200 Plant Ave., Wayne, PA 19087-3520 ("USAT") (each individually a "Party" and collectively, the "Parties").
Whereas:
(A) ZiLOG is a semiconductor company and has developed a web-enabled processor that may be used in the retail point of sale market;
(B) USAT has developed cashless payment technology, including credit or debit card payment technology as well as associated financial network systems, including its e-PortTM credit/debit card payment technology; and
(C) The Parties wish to establish a strategic alliance pursuant to which they will collaborate on certain projects including, (a) the design and development of a point of sale ("POS") reference design and development kit to be marketed by ZiLOG and (b) an eZ80 based e-port POS terminal to be marketed by USAT to its markets, based on a combination of ZiLOG's technology and expertise and USAT's technology and expertise.
NOW THEREFORE, in consideration of the premises and mutual covenants contained herein, the sufficiency and adequacy of which are acknowledged, and intending to be legally bound, the Parties agree as follows:
ARTICLE 1 - DEFINITIONS
Unless defined elsewhere in this Agreement, capitalized terms shall have the meanings set forth in this Article 1:
"Confidential Information" means, with respect to a Party, all proprietary or confidential material or information relating thereto obtained in connection with this Agreement. Confidential Information shall include all communications or data in any form including, without limitation, oral, written, graphic, electronic or electromagnetic form, which contain any information related to the disclosing Party and/or its products and/or its business including, without limitation, processes, patents, technology, know-how, techniques, improvements, inventions, business plans and strategies, marketing plans, product plans, trade secrets, customer lists, supplier lists, transaction methods and relationships between the disclosing Party and other entities, clients, financial records or information, phone numbers, addresses, security records and methods, formulas, development and marketing methods, designs, design practices, product or material sources and relationships, potential customers and listings, employee information (including, without limitation, employee identification, job titles, job duties and compensation), or contractor information, any information learned by the receiving Party in the process of examining any informa
141673
|
USA Technologies
As referenced in this Strategic Alliance Agreement:
USA Technologies,
Inc – by and between ZiLOG, Inc., a Delaware corporation having a place of
business at 532 Race Street, San Jose, CA 95126 ("ZiLOG"), and USA Technologies,
Inc ., a Pennsylvania corporation having a place of business at 200 Plant Ave.,
Wayne, PA 19087-3520 ("USAT") (each individually a "Party" and _____________
USA TECHNOLOGIES, INC – Agreement shall not affect its
interpretation.
In witness whereof, the Parties have executed this Agreement on the dates set
forth below.
Zilog INC. USA TECHNOLOGIES, INC .
By /S/ Mike Burger By /S/ Stephen P. Herbert
-------------------------- ----------------------------
Name: Mike Burger Name: Stephen P. Herbert
Title: President Title: President
Date: 10/ _____________
USA Technologies, Inc – ware sion software, loads/runs on a
single PC
---------------------------------- --------------------------------- --------------------------------
{/TABLE}
25
{PAGE}
Appendix E
USAT LICENSE TERMS
26
{PAGE}
SOFTWARE LICENSE AGREEMENT
Licensor:
USA Technologies, Inc .
200 Plant Avenue
Wayne, PA 19087
End User:
---------
-----------------------------------
-----------------------------------
-----------------------------------
-----------------------------------
Effective
Date:
-------------------------------
INTENDING TO BE LEGALLY BOUND, and in consideration of the mutual
agreements _____________
USA TECHNOLOGIES, INC – of Pennsylvania, without reference
to choice of law principles.
WITNESS THE DUE EXECUTION AND DELIVERY HEREOF AS OF THE DATE FIRST STATED
ABOVE.
USA TECHNOLOGIES, INC .
By:
-------------------------------
Name
and Title:
------------------------
END USER:
-------------------------
By:
------------------------------
Name
and Title:
------------------------
34
{PAGE}
Strategic Alliance Agreement Final Draft - October 14, 2002
Appendix F
_____________
dt 272604
;
|
ZiLOG
As referenced in this Strategic Alliance Agreement:
ZiLOG, – TEXT}
{PAGE}
Exhibit 10.39
STRATEGIC ALLIANCE AGREEMENT
This Agreement ("Agreement") is effective as of October 15, 2002 ("Effective
Date") by and between ZiLOG, Inc., a Delaware corporation having a place of
business at 532 Race Street, San Jose, CA 95126 ("ZiLOG"), and USA Technologies,
Inc., _____________
"ZiLOG" – Effective
Date") by and between ZiLOG, Inc., a Delaware corporation having a place of
business at 532 Race Street, San Jose, CA 95126 ("ZiLOG" ), and USA Technologies,
Inc., a Pennsylvania corporation having a place of business at 200 Plant Ave.,
Wayne, PA 19087-3520 ("USAT") (each _____________
ZiLOG – a place of business at 200 Plant Ave.,
Wayne, PA 19087-3520 ("USAT") (each individually a "Party" and collectively, the
"Parties").
Whereas:
(A) ZiLOG is a semiconductor company and has developed a web-enabled processor
that may be used in the retail point of sale market;
(B) _____________
ZiLOG – certain projects including, (a) the design and
development of a point of sale ("POS") reference design and development kit
to be marketed by ZiLOG and (b) an eZ80 based e-port POS terminal to be
marketed by USAT to its markets, based on a combination of ZiLOG' _____________
ZiLOG' – ZiLOG and (b) an eZ80 based e-port POS terminal to be
marketed by USAT to its markets, based on a combination of ZiLOG' s
technology and expertise and USAT's technology and expertise.
NOW THEREFORE, in consideration of the premises and mutual covenants contained
herein, the _____________
dt 217785
|
Preview
Full Doc
 | 2002 |
Strategic Alliance Agreement
Strategic Alliance Agreement (134K)
Doc #141716: Click preview link for longer preview.
STRATEGIC ALLIANCE AGREEMENT
This Strategic Alliance Agreement (this "Agreement"), dated as of April 29, 2002, by and between Intuit Inc., a Delaware corporation, having offices at 2535 Garcia Avenue, Mountain View, California 94043 ("Intuit"), Muriel Siebert & Co., Inc., a Delaware corporation, having offices at 885 Third Avenue, New York, New York 10022 ("Siebert") and, for purposes of Sections 1(e)(v), 4(a), 4(d) and 9(c), Investment Solution, Inc., a Delaware corporation ("ISI").
WHEREAS, Intuit is engaged in the business of providing personal finance software products and services, including, without limitation, its Quicken(R) desktop software products Quicken Basic, Quicken Deluxe, Quicken Home and Business and Quicken Suite (excluding TurboTax and any third party products contained therein) (collectively, "Quicken") and its Internet-based Quicken.com(TM) service ("Quicken.com") (collectively, the "Quicken Products");
WHEREAS, Siebert is engaged in the business of providing retail brokerage services for publicly traded securities, mutual funds and other related products;
WHEREAS, the parties desire to work together to develop, market and operate the Joint Brokerage Service (as defined herein); and
WHEREAS, ISI is an affiliate of Intuit that is applying for registration as a limited purpose broker-dealer and whose business will consist in part of referring users of the Quicken Products to the Joint Brokerage Service.
NOW, THEREFORE, in consideration of the mutual promises contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows (with certain capitalized terms having the meanings set forth in Section 13 hereof):
1. STRATEGIC ALLIANCE.
(a) Objective of the Strategic Alliance. The exclusive strategic alliance contemplated herein will be the vehicle whereby Intuit and Siebert together offer a joint brokerage service to customers as contemplated herein, Intuit as a technology, marketing and content provider and Siebert as a broker-dealer and provider of certain brokerage and other services.
(b) Development. The milestones for development of the Joint Brokerage Service are set forth in Exhibit A. The parties shall provide the specifications for, and the features and functionality for use by the customers of, the Joint Brokerage Service that are set forth in the definition of Joint Brokerage Service, the definition of Brokerage Platform and in Exhibit A.
(c) Customer Agreement. Prior to a customer's use of the Joint Brokerage Service, such customer shall enter into a customer agreement with Siebert in the form agreed upon by the parties and attached as Exhibit B hereto from time to time.
141716
|
Intuit
As referenced in this Strategic Alliance Agreement:
Intuit Inc. – 3
{FILENAME}x10-11.txt
{DESCRIPTION}STRATEGIC ALLIANCE EXHIBIT
{TEXT}
EXECUTION COPY
STRATEGIC ALLIANCE AGREEMENT
This Strategic Alliance Agreement (this "Agreement"), dated as of April
29, 2002, by and between Intuit Inc. , a Delaware corporation, having offices at
2535 Garcia Avenue, Mountain View, California 94043 ("Intuit"), Muriel Siebert &
Co., Inc., a Delaware corporation, having offices at 885 Third Avenue, New York,
_____________
Intuit Inc. – parties at the following
addresses (or at such other address for a party as shall be specified in a
notice given in accordance with this subsection (o)):
if to Intuit:
Intuit Inc.
2535 Garcia Avenue
Mountain View, California 94043
Attention: Fran Smallson
Telecopier: (650) 944-5656
with copies to:
Morgan, Lewis & Bockius LLP
101 Park Avenue
New York, New York 10178
_____________
INTUIT INC. – 35
{PAGE}
IN WITNESS WHEREOF, the parties, through their authorized officers,
have duly executed this Agreement intending it to be effective and binding as of
the date first written above.
INTUIT INC.
By: /s/ Lorri E. Norrington
-------------------------------------------
Name: Lorri E. Norrington
Title: Executive Vice President
Small Business and Personal Finance
FOR PURPOSES OF SECTIONS 1(e)(v), 4(a), 4(d)
_____________
dt 1469799
;
Siebert Financial Corp.
As referenced in this Strategic Alliance Agreement:
Siebert Financial Corp – now in effect or hereafter adopted by or
administered by the Exchanges or the SEC now or hereafter in effect.
(rrr) "SFC" means Siebert Financial Corp ., a New York corporation.
(sss) "Siebert" has the meaning set forth in the introductory
paragraph.
28
{PAGE}
(ttt) "Siebert Content" means the _____________
Siebert Financial Corp – Morgan, Lewis & Bockius LLP
101 Park Avenue
New York, New York 10178
Attention: Anne E. Gold
Telecopier: (212) 309-6273
if to Siebert:
Siebert Financial Corp oration
885 Third Avenue
Suite 1720
New York, New York 10022
Attention: Ms. Muriel Siebert
Telecopier: (212) 838-0647
with copies to:
Fulbright & _____________
dt 232810
;
Fulbright
As referenced in this Strategic Alliance Agreement:
Fulbright & Jaworski – York, New York 10022
Attention: Ms. Muriel Siebert
Telecopier: (212) 838-0647
with copies to:
Fulbright & Jaworski L.L.P.
666 Fifth Avenue
New York, New York 10103
Attention: Warren Nimetz
Telecopier: (
dt 36770
;
|
Morgan Lewis
As referenced in this Strategic Alliance Agreement:
Morgan, Lewis – Avenue
Mountain View, California 94043
Attention: Fran Smallson
Telecopier: (650) 944-5656
with copies to:
Morgan, Lewis & Bockius LLP
101 Park Avenue
New York, New York 10178
Attention: Anne E. Gold
dt 32458
;
Muriel Siebert & Co., Inc.
|
Preview
Full Doc
 | 2002 |
Strategic Alliance Agreement
Strategic Alliance Agreement (14K)
Doc #141721: Click preview link for longer preview.
Strategic Alliance
------------------
Between
Startech Environmental Corp. (Startech), a Colorado Corporation with its
principal office at 15 Old Danbury Road, Wilton, Connecticut 06897-2525 and
Hydro-Chem, a Division of the Pro-Quip Corporation, which is a subsidiary of
Linde AG, is a company with its principal office at 125 Hickory Springs
Industrial Drive, Canton, Georgia 30115.
Whereas, Startech has developed and commercialized a proprietary system and
process for the safe . . .
141721
|
Startech
As referenced in this Strategic Alliance Agreement:
Startech Environmental Corp. –
{DOCUMENT}
{TYPE}EX-10.U
{SEQUENCE}5
{FILENAME}startechex10u.txt
{DESCRIPTION}EX-10(U) STRATEGIC ALLIANCE AGREEMENT
{TEXT}
EXHIBIT 10(u)
Strategic Alliance
------------------
Between
Startech Environmental Corp. (Startech), a Colorado Corporation with its
principal office at 15 Old Danbury Road, Wilton, Connecticut 06897-2525 and
Hydro-Chem, a Division of the Pro-Quip Corporation, which is _____________
dt 1475329
;
| Hydro-Chem
|
Preview
Full Doc
 | 2002 |
Strategic Alliance Agreement [Amended and Restated]
Strategic Alliance Agreement [Amended and Restated] (218K)
Doc #141723: Click preview link for longer preview.
AMENDED AND RESTATED
STRATEGIC ALLIANCE AGREEMENT
BY AND BETWEEN
PENWEST PHARMACEUTICALS CO.
AND
ENDO PHARMACEUTICALS INC.
DATED AS OF APRIL 2, 2002
------------------------------
THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST IN ACCORDANCE WITH RULE 24b-2 OF THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN ***. {PAGE} TABLE OF CONTENTS
{TABLE} {S} {C} 1. Definitions............................................................. 1 2. [INTENTIONALLY OMITTED.]................................................ 2 3. Certification Period(s)................................................. 2 3.1 Covenants.......................................................... 2 3.2 Communication & Access............................................. 2 3.3 Reports............................................................ 2 3.4 Supply............................................................. 2 3.5 U.S. Certification Budget; Election Not to Continue Participation.. 2 3.6 Rest of the World.................................................. 4 3.7 Certification Reconciliations...................................... 4 4. Marketing Period........................................................ 5 4.1 Endo Covenants..................................................... 5 4.2 Penwest Covenants.................................................. 5 4.3 Rest of the World.................................................. 6 4.4 TIMERx Supply; Invoices During the Marketing Period................ 6 4.5 Royalties; Recoupment of Certification Excess...................... 7 4.6 Reduction in Royalties............................................. 7 4.7 Timing of Royalty Payments......................................... 8 4.8 Records; Audits.................................................... 9 4.9 Rate of Exchange for Non-U.S. Royalties............................ 9 5. Term and Termination.................................................... 9 5.1 Term............................................................... 10 5.2 Receipt of Non-Approvable Letter................................... 10 5.3 Mutual Agreement................................................... 10 5.4 Unfavorable or Inconclusive Results................................ 10 5.5 Termination of Participation in a Certification Period............. 10 5.6 Termination of an Exclusivity Period for Failure to Meet Minimum Net Realization Levels..................................... 11 5.7 Failure to Launch or Discontinuation of Active Marketing........... 11 5.8 Material Breaches.................................................. 11 5.9 Endo's Bankruptcy; Insolvency...................................... 12 5.10 Penwest's Bankruptcy; Insolvency................................... 12 5.11 Survival........................................................... 12 6. Ownership and Licenses.................................................. 12 6.1 Retention of Ownership; Inventorship; Assignment.................. 12 6.2 Filing and Prosecution of Patents.................................. 13 6.3 Licenses Granted................................................... 13 6.4 Exclusivity........................................................ 14 6.5 Licenses as to Product Technology.................................. 15 6.6 Endo's License to TIMERx........................................... 15 6.7 Endo's Continuing License.......................................... 15 {/TABLE}
i {PAGE} {TABLE} {S} {C} 6.8 Penwest's Continuing License....................................... 17 6.9 License to Improvement Technology.................................. 19 6.10 License to Endo Test and Regulatory Data........................... 20 6.11 License to Penwest Test and Regulatory Data........................ 20 6.12 Marking of the Product............................................. 21 7. Supply of TIMERx; Oxymorphone........................................... 21 7.1 Sales of TIMERx.................................................... 21 7.2 Quality Control Testing............................................ 21 7.3 Non-Conforming Shipments........................................... 21 7.4 Failure to Supply TIMERx........................................... 22 7.5 Failure to Supply Oxymorphone ADS or Finished Product.............. 23 7.6 Access............................................................. 24 7.7 TIMERx Ordering Process............................................ 25 7.8 Estimates of TIMERx................................................ 25 7.9 Actual TIMERx Supply............................................... 25 7.10 Notifications; Governmental Inspections............................ 25 7.11 Manufacturing Agreements........................................... 26 8. Use of Trademarks....................................................... 27 8.1 Benefit of Trademarks.............................................. 27 8.2 Protection of Trademarks........................................... 27 8.3 Acknowledgement of Ownership of Trademarks......................... 27 8.4 Prior Approval of Use of Trademarks................................ 28 9. Representations, Warranties and Indemnities............................. 28 9.1 Mutual Authorization Representations............................... 28 9.2 Penwest Representations............................................ 28 9.3 Mutual Licenses, Permits and Authorizations Representations........ 29 9.4 Disclaimer......................................................... 29 9.5 Penwest's Indemnification of Endo.................................. 29 9.6 Endo's Indemnification of Penwest.................................. 30 9.7 Limitation on Indemnification...................................... 30 9.8 Procedure.......................................................... 31 9.9 No Liability....................................................... 31 10. Confidentiality and Non-Solicitation.................................... 32 10.1 Confidentiality; Exceptions........................................ 32 10.2 Public Announcements............................................... 33 10.3 Non-Solicitation................................................... 33 11. Infringement............................................................ 33 11.1 Notice of Infringement............................................. 33 11.2 Non-Covered Infringement........................................... 34 11.3 Penwest's Institution of Suit...................................... 34 11.4 Joint Suits........................................................ 34 11.5 Endo's Institution of Suit......................................... 34 11.6 Abandonment of Suit................................................ 34 11.7 Patent Enforcement Litigation...................................... 35 {/TABLE}
ii {PAGE} {TABLE} {S} {C} 12. Escalation Procedures................................................... 35 13. Arbitration............................................................. 36 14. Miscellaneous........................................................... 37
Exhibits Definitions Exhibit......................................................... 40 Exhibit 1.17 - Trademarks................................................... 52 Exhibit 1.28 - Accounting and Attribution Standards and Principals.......... 53 Exhibit 1.32 - Penwest Patents.............................................. 56 Exhibit 6.1 - Certain Jointly Filed Provisional Patent Applications......... 58 {/TABLE}
iii {PAGE} AMENDED AND RESTATED
STRATEGIC ALLIANCE AGREEMENT
THIS AGREEMENT is entered into as of the 2nd day of April, 2002 (the "Restatement Date"), by and between Penwest Pharmaceuticals Co. ("Penwest"), a Washington corporation with its principal place of business at 2981 Route 22, Patterson, New York 12563, and Endo Pharmaceuticals Inc., a Delaware corporation with its principal place of business at 100 Painters Drive, Chadds Ford, Pennsylvania 19317 ("Endo").
WHEREAS, Penwest and Endo are party to that certain Strategic Alliance Agreement, dated as of September 17, 1997 (the "Old Agreement");
WHEREAS, in light of changes that have occurred at both Penwest and Endo since the execution of the Old Agreement, Penwest and Endo now wish to amend and restate the Old Agreement in its entirety;
WHEREAS, Penwest has developed an extended-release agent covered by one or more patents, patent applications, know-how and other proprietary technology, which agent Penwest markets under the name and mark "TIMERx(R)" ("TIMERx");
WHEREAS, Endo manufactures and markets the product marketed under the name "Numorphan(R)", having as an active drug substance oxymorphone HCl ("Oxymorphone") and has developed know-how and other proprietary technology with respect thereto;
WHEREAS, the parties, pursuant to the Old Agreement, have co-developed a product combining Oxymorphone and TIMERx, which product is a solid-dosage extended-release pharmaceutical for oral administration in humans in one or more dosage strengths and which product is referred to by the parties as "EN 3202";
WHEREAS, the parties desire to provide for the further development and commercialization of EN 3202 as provided herein; and
WHEREAS, Endo desires to contract for a supply of TIMERx for use in the manufacture of EN 3202, and Penwest is willing to supply the same provided that Endo agrees to obtain all of its and its Affiliates' and sublicensees' requirements of TIMERx from Penwest as provided herein;
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
1. Definitions. Certain terms used herein are defined in Sections 1.1 through 1.44 of the Definitions Exhibit attached hereto and incorporated herein by this reference.
141723
|
Penwest Pharma
As referenced in this Strategic Alliance Agreement [Amended and Restated]:
PENWEST PHARMACEUTICALS – y60437ex10-18.txt
{DESCRIPTION}A/R STRATEGIC ALLIANCE AGREEMENT
{TEXT}
{PAGE}
Exhibit 10.18
AMENDED AND RESTATED
STRATEGIC ALLIANCE AGREEMENT
BY AND BETWEEN
PENWEST PHARMACEUTICALS CO.
AND
ENDO PHARMACEUTICALS INC.
DATED AS OF APRIL 2, 2002
------------------------------
THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN FILED SEPARATELY
WITH THE _____________
Penwest Pharmaceuticals – RESTATED
STRATEGIC ALLIANCE AGREEMENT
THIS AGREEMENT is entered into as of the 2nd day of April, 2002 (the
"Restatement Date"), by and between Penwest Pharmaceuticals Co. ("Penwest"), a
Washington corporation with its principal place of business at 2981 Route 22,
Patterson, New York 12563, and Endo Pharmaceuticals Inc., _____________
PENWEST PHARMACEUTICALS – hereto have caused their duly
authorized officers to execute and acknowledge this Agreement as of the date
first written above.
ENDO PHARMACEUTICALS INC. PENWEST PHARMACEUTICALS CO.
By: /s/ CAROL A. AMMON By: /s/ TOD R. HAMACHEK
--------------------------------- --------------------------------------
Its: Chairman & CEO Its: Chairman & CEO
--------------------------------- --------------------------------------
Address: Address:
100 Painters Drive 2981 _____________
Penwest Pharmaceuticals – promotion of the Product hereunder, pursuant to Section 8
hereof.
1.18 "Escalation Officer" shall mean the Chairman and Chief
Executive Officer of Penwest Pharmaceuticals Co. (currently
Tod Hamachek), and the Chief Executive Officer of Endo
(currently Carol Ammon), and the persons holding such
positions from time to _____________
dt 137335
;
Hale and Dorr
As referenced in this Strategic Alliance Agreement [Amended and Restated]:
Hale and Dorr – A. Ammon Attn: Tod R. Hamachek
cc: Steven D. Singer, Esq.
cc: Caroline B. Manogue Hale and Dorr LLP
FAX: (610) 558-9684 60 State Street
Boston, Massachusetts 02109
FAX: (617) 526-
dt 37113
;
| Endo Pharmaceuticals Inc.;
Endo Pharmaceuticals Holdings Inc.
|
Preview
Full Doc
 | 2002 |
Strategic Alliance Agreement [Form]
Strategic Alliance Agreement [Form] (55K)
Doc #141741: Click preview link for longer preview.
STRATEGIC ALLIANCE AGREEMENT
This STRATEGIC ALLIANCE AGREEMENT ("Agreement") is entered into as of _______ __, 2002 ("Effective Date") by QUANTUM FUEL SYSTEMS TECHNOLOGIES WORLDWIDE, INC., a Delaware corporation ("Quantum") and IMPCO TECHNOLOGIES, INC., a Delaware corporation ("IMPCO"), each a "Party" and collectively the "Parties."
RECITALS
A. Quantum designs, develops and manufactures advanced gaseous storage and handling modules, electronic controls and software, fuel storage, metering, regulating and delivery systems, and systems integration involving compressed gaseous fuels and supplies the same to original equipment manufacturers ("OEMs") for fuel cell applications and alternative fuel OEM vehicles.
B. IMPCO designs and develops, among other things, components and sub-systems for internal combustion engines utilizing alternative fuels.
C. The Parties seek to cooperate with each other under this Agreement, on the terms and conditions specified herein, (1) in performing joint development activities funded by IMPCO, and (2) in participating in joint marketing activities.
D. The Parties wish to set forth herein the terms and conditions upon which Quantum agrees to sell to IMPCO the Quantum Products (defined below), for use in the Designated Markets.
AGREEMENT
1 DEFINITIONS.
1.1 "Commercially Available" means that the relevant product is generally made available to customers, regardless of whether such customer: (a) is an end user of the product; (b) subsequently sells the product as a stand-alone item; and/or (c) integrates the product as a component of the customer's or third party's product.
1.2 "Confidential Information" has the meaning set forth in Section 9.1.
1.3 "Customer" means any third party that has entered into an agreement with IMPCO to obtain an IMPCO Product that includes, incorporates or utilizes any Quantum Product.
1.4 "Designated Markets" means the following: (a) the worldwide automotive Aftermarket, consisting of Class 1 through Class 5 vehicles; (b) the worldwide bus and truck Aftermarket, consisting of Class 6 through Class 8 vehicles; (c) the worldwide industrial Aftermarket consisting of, without limitation, material handling, small and stationary engines, generators, pumps and other products not used for transportational purposes; (d) the worldwide diesel automotive Aftermarket, consisting of Class 1 through 5 diesel vehicles; (e) the worldwide diesel bus and truck Aftermarket, consisting of Class 6 through Class 8 diesel vehicles; (f) the worldwide industrial diesel Aftermarket, consisting of, without limitation, material handling, small and stationary engines, generators, pumps and other diesel products not used for transportational purposes; (g) the worldwide market for original equipment manufacturers of
141741
|
IMPCO
As referenced in this Strategic Alliance Agreement [Form]:
IMPCO TECHNOLOGIES, – Agreement") is entered into as of
_______ __, 2002 ("Effective Date") by QUANTUM FUEL SYSTEMS TECHNOLOGIES
WORLDWIDE, INC., a Delaware corporation ("Quantum") and IMPCO TECHNOLOGIES,
INC., a Delaware corporation ("IMPCO"), each a "Party" and collectively the
"Parties."
RECITALS
A. Quantum designs, develops and manufactures advanced gaseous storage _____________
IMPCO Technologies, – 92614 Santa Monica, CA 90404
Attention: Allen Niedzwiecki Attention: Charles L. Crouch
Fax: (949) 399-4600 Fax: (310) 788-3399
If to IMPCO: IMPCO Technologies, Inc. With a Morrison & Foerster, LLP
16804 Gridley Place copy to: 555 West 5th Street
Cerritos, CA 90703 35th Floor
Attention: Chief _____________
IMPCO TECHNOLOGIES, – WITNESS WHEREOF, the Parties, by their duly authorized representatives,
have executed this Strategic Alliance Agreement as of the Effective Date.
QUANTUM FUEL SYSTEMS IMPCO TECHNOLOGIES, INC.
TECHNOLOGIES, WORLDWIDE, INC.
By:___________________________________ By:___________________________________
Name:_________________________________ Name:_________________________________
Title:________________________________ Title:________________________________
EXHIBITS
--------
A TEMPLATE -- STATEMENT OF WORK
_____________
dt 223091
;
Quantum Fuel
As referenced in this Strategic Alliance Agreement [Form]:
QUANTUM FUEL SYSTEMS TECHNOLOGIES
WORLDWIDE, – PAGE}
EXHIBIT 10.5
STRATEGIC ALLIANCE AGREEMENT
This STRATEGIC ALLIANCE AGREEMENT ("Agreement") is entered into as of
_______ __, 2002 ("Effective Date") by QUANTUM FUEL SYSTEMS TECHNOLOGIES
WORLDWIDE, INC., a Delaware corporation ("Quantum") and IMPCO TECHNOLOGIES,
INC., a Delaware corporation ("IMPCO"), each a "Party" and collectively the
"Parties."
RECITALS
A. _____________
dt 223193
;
|
Perkins Coie
As referenced in this Strategic Alliance Agreement [Form]:
Perkins Coie – follows:
{TABLE}
{S} {C} {C} {C}
If to Quantum: QUANTUM FUEL SYSTEMS TECHNOLOGIES With a Perkins Coie LLP
WORLDWIDE, INC. copy to: 1620 26th Street
17872 Cartwright Road 6th Floor
Irvine,
dt 33035
|
Preview
Full Doc
 | 2001 |
Marketing Alliance Agreement
Marketing Alliance Agreement (161K)
Doc #146829: Click preview link for longer preview.
MARKETING ALLIANCE AGREEMENT
MARKETING ALLIANCE AGREEMENT dated as of March 20, 2001 among CANADIAN IMPERIAL BANK OF COMMERCE, a bank formed under the laws of Canada (the "Bank"), and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation ("NDPS"), GLOBAL PAYMENTS CANADA INC. an Ontario corporation ("GPI CANADA") and GLOBAL PAYMENTS INC. a Georgia corporation ("GLOBAL PAYMENTS") as the guarantor of NDPS' and GPI Canada's obligations hereunder, as described on the last page of this Agreement.
WHEREAS, the Bank and NDPS (and National Data Corporation and Global Payments as the guarantors of NDPS' obligations) entered into an Asset Purchase Agreement dated November 9, 2000 (the "ASSET PURCHASE AGREEMENT"), pursuant to which the Bank agreed to sell to NDPS the Assets Sold (as defined therein);
WHEREAS, the parties have each agreed to undertake or cause to be undertaken certain activities with respect to the Merchant Business;
WHEREAS, it was a condition to the consummation of the transactions provided for in the Asset Purchase Agreement that the Bank and NDPS enter into this Marketing Alliance Agreement;
NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants contained herein, the Bank and NDPS agree as follows:
SECTION 1. DEFINITIONS AND INTERPRETATION
SECTION 1.1 CERTAIN DEFINED TERMS. For purposes of this Agreement, the following terms shall have the following meanings:
"ACCOUNT FEES" has the meaning set forth in Section 5.2.
"ADVISORS" means, with respect to a Person, the Person's employees, agents, professional advisors and consultants and "ADVISOR" means any one of them.
"AFFILIATES" means, with respect to the Person specified, a Person that Controls or is Controlled by, or is under common Control with, the Person specified.
"AGGREGATE TRANSACTION VOLUME" has the meaning set forth in Section 8.3(e).
"AMICUS" has the meaning set forth in Section 8.3(b).
"ARBITRATION" has the meaning set forth in Section 22.5.
"ARBITRATION ACT" has the meaning set forth in Section 22.5.
"ASSET PURCHASE AGREEMENT" has the meaning set forth in the Recitals.
1 {PAGE}
"ASSIGNED MERCHANT AGREEMENTS" means the Existing Merchant Agreements (but not the Excluded Merchant Agreements).
"ASSOCIATION RULES" means the rules and regulations established from time to time by a Credit Card Association or Network Organization.
"BANK DATA" means all data and information, including, but not limited to, personal information, account balance information, facts, records, business data tapes and documents, relating to the Bank's businesses (other than the Merchant Business or information which has otherwise been disclosed by a Merchant or a customer to NDPS and/or GPI Canada directly or is available in the public domain).
"BANK DEFAULT" has the meaning set forth in Section 14.2.
"BANK MARKS" means the Bank's trade name and trade-marks specifically identified in the Trademark Licence Agreement.
"BANK SERVICE LOCATION" means any location where the Bank performs Bank Services.
"BANK SERVICES" means the services to be provided by, and all other obligations of, the Bank expressly provided for in this Agreement in fulfilment of obligations under the Merchant Agreements, including the Transition Services for so long as, and to the extent that, they are provided under the Transition Agreement.
"BANK'S U.S. ICAS/BINS" has the meaning set forth in Section 8.3(b).
"BIN" means a Bank Identification Number used in connection with Credit Card Transactions, as described in greater detail in the applicable Association Rules.
"BIN REPORTING" has the meaning set forth in Section 8.2.
"BUSINESS DAY" means any day excluding Saturday, Sunday and any day on which banking institutions located in Toronto, Ontario, St. Louis, Missouri or Atlanta, Georgia are authorized by law or other governmental action to be closed.
"BUSINESS RECOVERY PLANS" means, as the case may be, NDPS' and/or GPI Canada's business recovery procedures with respect to the Merchant Business to be implemented by NDPS and GPI Canada pursuant to the conditions imposed by the Office of the Superintendent of Financial Institutions in its conditional order permitting NDPS to process data relating to the Merchant Business from a location outside Canada, and under the Transition Agreement, such procedures may be updated and modified from time to time in accordance with the terms of this Agreement, and the Bank's business recovery procedures with respect to the Bank Services, as such procedures may be modified from time to time in accordance with the terms of this Agreement.
146829
|
Global Payments
As referenced in this Marketing Alliance Agreement:
GLOBAL PAYMENTS
INC – the "Bank"),
and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation ("NDPS"), GLOBAL
PAYMENTS CANADA INC. an Ontario corporation ("GPI CANADA") and GLOBAL PAYMENTS
INC . a Georgia corporation ("GLOBAL PAYMENTS") as the guarantor of NDPS' and GPI
Canada's obligations hereunder, as described on the last page _____________
Global Payments Inc – if any, of
5
{PAGE}
Global Payments, and an officer or officers of the Bank designated by the Bank)
and two directors of Global Payments Inc . designated by NDPS.
"KEY ACCOUNTS" has the meaning set forth in Section 2.7.
"KEY ACCOUNT NOTICE" has the meaning set forth _____________
Global Payments Inc – Toronto, Ontario M5L 1A9
47
{PAGE}
Attn: Managing Partner
Facsimile: (416) 863-2653
(b) If to NDPS, Global Payments
or GPI Canada to: Global Payments Inc .
#4 Corporate Square
Atlanta, Georgia 30329-2010
Attn.: Office of the Corporate Secretary
Facsimile: (404) 728-2990
The persons or addresses to _____________
GLOBAL PAYMENTS INC – P. Tornay
Title: General Counsel
The obligations of National Data Payment Systems, Inc. and Global Payments
Canada Inc. hereunder are hereby guaranteed by GLOBAL PAYMENTS INC .
GLOBAL PAYMENTS INC.
By: /s/ Suellyn P. Tornay
---------------------------------------
Name: Suellyn P. Tornay
Title: General Counsel
51
{PAGE}
SCHEDULE 2.5
NEW MERCHANT _____________
GLOBAL PAYMENTS INC – General Counsel
The obligations of National Data Payment Systems, Inc. and Global Payments
Canada Inc. hereunder are hereby guaranteed by GLOBAL PAYMENTS INC.
GLOBAL PAYMENTS INC .
By: /s/ Suellyn P. Tornay
---------------------------------------
Name: Suellyn P. Tornay
Title: General Counsel
51
{PAGE}
SCHEDULE 2.5
NEW MERCHANT AGREEMENTS
To be _____________
dt 269365
;
CIBC
As referenced in this Marketing Alliance Agreement:
CANADIAN
IMPERIAL BANK OF COMMERCE, – txt
{DESCRIPTION}MARKETING ALLIANCE AGREEMENT
{TEXT}
{PAGE}
Exhibit 10.3
MARKETING ALLIANCE AGREEMENT
MARKETING ALLIANCE AGREEMENT dated as of March 20, 2001 among CANADIAN
IMPERIAL BANK OF COMMERCE, a bank formed under the laws of Canada (the "Bank"),
and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation ("NDPS"), GLOBAL
_____________
Canadian Imperial Bank of Commerce
– SECTION 23.2 NOTICES. All notices required hereunder shall be delivered to the
following names and addresses:
(a) If to the Bank, to: Canadian Imperial Bank of Commerce
c/o CIBC World Markets Inc.
161 Bay Street, BCE Place,7th Floor
Toronto, Ontario M5J 2J8
Attn: Executive Vice President, Card _____________
Canadian Imperial Bank of Commerce
– Toronto, Ontario M5J 2J8
Attn: Executive Vice President, Card Products,
Collections and Merchant Card Services
Facsimile: (416) 784-6868
with a copy to:
Canadian Imperial Bank of Commerce
Legal and Compliance Division
199 Bay Street, 15th Floor
Commerce Court West
Toronto, Ontario M5L 1A2
Attn: General Counsel
Facsimile: (416) 304- _____________
CANADIAN IMPERIAL BANK OF COMMERCE
– parties hereto have caused this agreement to be executed
by their respective officers thereunto duly authorized, as of the date first
above written.
CANADIAN IMPERIAL BANK OF COMMERCE
By: /s/ Christine Croucher
---------------------------------------
Name: Christine Croucher
Title:
By: /s/ David A. Caldwell
---------------------------------------
Name: David A. Caldwell
Title:
NATIONAL DATA PAYMENT SYSTEMS, _____________
dt 243670
;
| National Data Payment Systems, Inc.;
Global Payments Canada Inc.
|
Preview
Full Doc
 | 2001 |
Strategic Alliance Agreement
Strategic Alliance Agreement (56K)
Doc #146854: Click preview link for longer preview.
STRATEGIC ALLIANCE AGREEMENT BETWEEN GOAMERICA INC. AND RESEARCH IN MOTION LIMITED
THIS STRATEGIC ALLIANCE AGREEMENT (the "Agreement") is entered into as of the 1st day of July, 2000, by and among GOAMERICA INC. ON BEHALF OF ITSELF AND OTHER AFFILIATED CORPORATIONS (hereinafter referred to as "GoAmerica"), a corporation organized under the laws of Delaware, United States of America, with its principal office at 401 Hackensack Avenue, Hackensack, NJ 07601, and RESEARCH IN MOTION LIMITED (hereinafter referred to as "RIM"), a corporation organized under the laws of Ontario, Canada, having principal offices at 295 Phillip Street, Waterloo, Ontario, Canada, N2L 3W8; the above parties are individually and/or collectively referred to herein as the "Party" or "Parties".
WITNESSETH:
WHEREAS, the Parties have determined that they would benefit from a joint arrangement among their respective organizations to market the RIM BlackBerry Solution and certain RIM Wireless Handheld Devices for Mobitex and Datatac Networks (the "Handheld" or "Handhelds") with GoAmerica's "Go.Web" software application which allows Internet access via wireless handheld devices (the "Application") [the RIM BlackBerry Solution, Handhelds and the Application are individually and/or collectively referred to herein as the "Product" or "Products"]; and
WHEREAS, the Parties desire to enter into this Agreement in order to define a business relationship to support and accomplish the above business objective through coordinated marketing arrangements; and
WHEREAS, the Parties have entered into a Preliminary Marketing Agreement (the "PMA") dated May 3, 2000 wherein the Parties agreed to enter into a Strategic Alliance Agreement;
NOW, THEREFORE, in consideration of the mutual promises hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
1 RIM ______ GoAmerica _______ {PAGE} 2
1 SCOPE
1.1 During the Term of this Agreement as hereinafter defined, the Parties will work together to offer and market the BlackBerry Solution with the Application to end-user customers buying directly from RIM.
2 TERM
2.1 The term of this Agreement ("Term") shall be for a period of one (1) year from July 31, 2000 (the "Effective Date"). This Agreement shall be automatically renewed for additional one-year periods unless terminated by either Party with thirty (30) days written notice to the other Party prior to the end of the Term or any renewal Term.
3 REPRESENTATIONS AND WARRANTIES
3.1 GoAmerica represents and warrants that it either owns or is authorized to sublicense a software application, "Go.Web" (the "Application"), described in Schedule A attached hereto, which allows Internet access via wireless handheld devices. GoAmerica hereby grants RIM the right to use the Application in conjunction with the Handhelds and the RIM BlackBerry Solution.
3.2 GoAmerica warrants to RIM that the Application hereunder will be free from significant programming errors, will be delivered on media that are free from defects in workmanship and materials, will operate in conformity with the performance capabilities, specifications and functions of such Application, and will conform to the standards generally observed in the industry for similar software applications. GoAmerica shall be solely responsible for providing any and all End-User Warranties relating to the Application. Except as expressly provided in this Agreement, no other warranties, express or implied, are made by GoAmerica.
3.3 GoAmerica warrants that none of: (a) the Application, (b) any upgrades, enhancements or other modifications to the Application developed by or on behalf of GoAmerica and incorporated into the Application or otherwise provided to RIM, or (c) any documentation provided by GoAmerica to RIM along with the Application will infringe or violate, as the case may be, any patents or trademarks registered or enforceable in the United States or Canada, trade names, and copyrights, trade secrets or other intellectual property or proprietary rights.
3.4 GoAmerica warrants that to the best of its knowledge the Application, when integrated with the Handhelds and/or the BlackBerry Solution, will not infringe or violate, as the case may be, any patents or trademarks registered or enforceable in the United States or Canada, trade names, and copyrights, trade secrets or other intellectual property or proprietary rights.
146854
|
GoAmerica
As referenced in this Strategic Alliance Agreement:
GOAMERICA INC – 1
EXHIBIT 10.24
Confidential Materials omitted and filed separately with
the Securities and Exchange Commission.
Asterisks denote omissions.
STRATEGIC ALLIANCE AGREEMENT
BETWEEN
GOAMERICA INC .
AND
RESEARCH IN MOTION LIMITED
THIS STRATEGIC ALLIANCE AGREEMENT (the "Agreement") is entered into as of the
1st day of July, 2000, _____________
GOAMERICA INC – IN MOTION LIMITED
THIS STRATEGIC ALLIANCE AGREEMENT (the "Agreement") is entered into as of the
1st day of July, 2000, by and among GOAMERICA INC . ON BEHALF OF ITSELF AND OTHER
AFFILIATED CORPORATIONS (hereinafter referred to as "GoAmerica"), a corporation
organized under the laws of Delaware, United _____________
GOAMERICA INC – have caused this Agreement to be executed by
their duly authorized representatives as of the dates set forth below.
RESEARCH IN MOTION LIMITED GOAMERICA INC .
By: /s/ Jim Balsillie By: /s/ Joe Korb
Name: Jim Balsillie Name: Joe Korb
Title: Chairman and Co-CEO Title: President
16
_____________
dt 276506
;
| Research in Motion Limited
|
Preview
Full Doc
 | 2003 |
Joint Marketing and Alliance Agreement
Joint Marketing and Alliance Agreement (105K)
Doc #163992: Click preview link for longer preview.
JOINT MARKETING AND ALLIANCE AGREEMENT THIS JOINT MARKETING AND ALLIANCE AGREEMENT (this Agreement) is made and entered into as of October 7, 2003 (the Effective Date), by and among Answerthink, Inc., a Florida corporation, with offices at 1001 Brickell Bay, Suite 3000, Miami, Florida 33131 (Answerthink), The Hackett Group, Inc., an Ohio corporation and a wholly-owned subsidiary of Answerthink (Hackett), and Accenture LLP, an Illinois general partnership registered as a limited liability partnership, with an office at Suite 1300, 100 Peachtree Street, NE, Atlanta, GA 30303 (Accenture). ARTICLE 1 OVERVIEW 1.1 Background. Answerthink provides the following services to clients: strategy formulation, business case development, business process design, process improvement, systems design and implementation (including, without limitation, package or custom software design and package or custom software implementation), organization design, and organization change (collectively referred to as Answerthink Services). Hackett, a wholly-owned subsidiary of Answerthink, is a developer, marketer, and provider of benchmarking services which measure and evaluate the practices and performance of a business enterprise as compared to other enterprises practices and performances (Hackett Benchmarking Services) and best practice related published research and executive education (collectively referred to as Hackett Research and Education Services and, collectively with Hackett Benchmarking Services, as Hackett Services). Accenture provides services to clients, including, but not limited to, systems design and management, modifications to clients current business systems and processes, identification of operational strategies, implementation and conversion assistance, organization design and conversion training, outsourcing, designing, developing and providing application software systems, support, installation services and education to clients, and integrating its services and those supplied by other vendors to meet the needs of clients (collectively referred to as Accenture Services). 1.2 Purpose. The parties wish to form a joint marketing and alliance relationship (the Alliance) in order to increase the value delivered to existing clients and the probability of winning new clients. The parties will attempt to further this purpose through joint marketing, business development, solution delivery and relationship management activities The parties may also, pursuant to a separately negotiated agreement, engage in capability or asset development efforts. 1.3 Scope of Business Development Efforts. The services scope of this alliance is primarily focused on the Answerthink Services and the Hackett Benchmarking Services (collectively, the Alliance Services) related to the functional areas listed on Exhibit A (collectively, the Alliance Functional Areas). The functional scope of this Alliance shall be limited to Alliance Functional Areas in any industry; provided, however, pursuant to Article 4
hereof, the parties may explore additional functional areas and, from time to time, modify Exhibit A to reflect functional areas added to the scope of the Alliance as agreed by the parties. The initial focus of the parties business development efforts will be primarily on the Products, Communications & High Tech, and Resources industries. The Government and Financial Services sectors will be a secondary focus. Initially, the geographic scope of this Alliance will be North America, although the parties intend to expand that geographic scope as opportunities, individual resources and joint plans evolve. 1.4 Expansion of Geographic Scope and Implementation In Other Countries. In order to implement the Alliance on a global scale, the parties plan to enter into local country addenda between their Affiliates in other geographies, as agreed from time-to-time. Accenture Affiliate means any entity, whether incorporated or not, that is controlled by, under common control with, or controls Accentures ultimate parent company, Accenture Ltd. Answerthink Affiliate means any entity, whether incorporated or not, that is controlled by, under common control with, or controls Answerthink. Control means the ability, whether directly or indirectly, to direct the affairs of another by means of ownership, contract or otherwise. Specific implementation of this relationship in countries other than the United States may require that Accenture and/or an Accenture Affiliate in the country execute a local country addendum with Answerthink and Hackett and/or an Answerthink Affiliate in such country. The parties intend that such addenda will not modify the terms of this Agreement, except to the extent necessary to reflect local and/or governmental business conditions and legal requirements, and will not relieve the parties of financial responsibility to one another for Alliance activities. 1.5 Nature of Relationship. Nothing in this Agreement or any related documents is intended to, or shall be deemed to create a corporation, partnership, joint venture, or other legal entity of any kind or for any purpose as between the parties. Neither party shall have any authority to, or shall attempt to, bind or commit the other party for any purpose without the express written consent of the other. 1.6 Other Opportunities. Answerthink and Hackett will not enter into an alliance or joint proposal with any competitor of Accenture that includes Alliance Services in the Alliance Functional Areas and would use Hacketts Benchmarking Services within the scope of the alliance or joint proposal. Notwithstanding the foregoing, each party shall, at all times remain free to decline to pursue a specific opportunity in its discretion and may work with another product or services provider based on a client request. 1.7 Other Relationships. This Agreement is expressly made subject to, and does not interfere with or alter, those existing relationships or contractual obligations between each party (or its Affiliates) and its partners, clients, service providers and other third parties, which are disclosed on Exhibit F. ARTICLE 2 TEAMING 2.1 Teaming Relationships. With respect to certain clients, Answerthink and Hackett will be the provider of Hackett Benchmarking Services to clients, while Accenture will
163992
|
Accenture
As referenced in this Joint Marketing and Alliance Agreement:
Accenture Ltd – Accenture Affiliate means any entity, whether incorporated or not, that is controlled by, under common control with, or controls Accentures ultimate parent company, Accenture Ltd . Answerthink Affiliate means any entity, whether incorporated or not, that is controlled by, under common control with, or controls Answerthink. Control means _____________
dt 259239
;
Affiliated
As referenced in this Joint Marketing and Alliance Agreement:
Affiliated Computer Services Inc. – have continuing mutual obligations to provide sales and technical support for that product through April 2004.
1
EXHIBIT G
PRINCIPAL ACCENTURE COMPETITORS
International Business Machines Corporation
Electronic Data Systems Corporation
Affiliated Computer Services Inc.
Exult, Inc.
Deloitte Consulting
Booz Allen Hamilton Inc.
BearingPoint, Inc.
Cap Gemini Ernst &Young
Hewlett Packard Company
1
_____________
dt 1446912
;
Answerthink
As referenced in this Joint Marketing and Alliance Agreement:
Answerthink, Inc. – portions. *****
JOINT MARKETING AND ALLIANCE AGREEMENT
THIS JOINT MARKETING AND ALLIANCE AGREEMENT (this Agreement) is made and entered into as of October 7, 2003 (the Effective Date), by and among Answerthink, Inc. , a Florida corporation, with offices at 1001 Brickell Bay, Suite 3000, Miami, Florida 33131 (Answerthink), The Hackett Group, Inc., an Ohio corporation and a wholly-owned subsidiary of Answerthink ( _____________
Answerthink, Inc. – With copies of any notice to:
Attn: General Counsel
Accenture LLP
1661 Page Mill Rd.
Palo Alto, CA 94304
Facsimile No.: (650) 213-2222
If intended for Answerthink or Hackett:
Answerthink, Inc.
Attn: Ted Fernandez, Chairman and CEO
1001 Brickell Bay, Suite 3000
Miami, Florida 33131
Facsimile No.: (305) 379-4736
With copies of any notice to:
Answerthink, Inc.
Attn: General _____________
Answerthink, Inc. – Answerthink or Hackett:
Answerthink, Inc.
Attn: Ted Fernandez, Chairman and CEO
1001 Brickell Bay, Suite 3000
Miami, Florida 33131
Facsimile No.: (305) 379-4736
With copies of any notice to:
Answerthink, Inc.
Attn: General Counsel
1001 Brickell Bay, Suite 3000
Miami, Florida 33131
Facsimile No. (305) 702-7000
ARTICLE 16
GENERAL PROVISIONS
16.1 Non-assignment. Neither this Agreement nor any _____________
ANSWERTHINK, INC. – the confidentiality of the terms hereof.
20
IN WITNESS WHEREOF, the parties hereto have executed this Joint Marketing and Alliance Agreement as of the date first written above.
ACCENTURE LLP
ANSWERTHINK, INC.
/s/ Michael R. Sutcliff
/s/ Ted A. Fernandez
Authorized Signature
Authorized Signature
Michael R. Sutcliff
Name:
Name: Ted A. Fernandez
Title:
Title: Chairman and CEO
Global Managing Partner, F& _____________
Answerthink, Inc. – entered into as of , 20 , by and between Accenture LLP, an Illinois partnership with an office at Suite 1300, 100 Peachtree Street, NE, Atlanta, GA 30303 (Accenture or Consultant) and Answerthink, Inc. , a Florida corporation, with offices at 1001 Brickell Bay, Suite 3000, Miami, Florida 33131 (Subcontractor).
WHEREAS, Consultant, Subcontractor and Subcontractors wholly-owned subsidiary, the Hackett Group, Inc. have entered _____________
dt 1446953
;
|
Computer
As referenced in this Joint Marketing and Alliance Agreement:
Computer Services Inc. – continuing mutual obligations to provide sales and technical support for that product through April 2004.
1
EXHIBIT G
PRINCIPAL ACCENTURE COMPETITORS
International Business Machines Corporation
Electronic Data Systems Corporation
Affiliated Computer Services Inc.
Exult, Inc.
Deloitte Consulting
Booz Allen Hamilton Inc.
BearingPoint, Inc.
Cap Gemini Ernst &Young
Hewlett Packard Company
1
_____________
dt 1322558
;
More... |
Preview
Full Doc
 | 2003 |
Strategic Alliance Agreement
Strategic Alliance Agreement (141K)
Doc #184359: Click preview link for longer preview.
STRATEGIC ALLIANCE AGREEMENT
between
THE GILLETTE COMPANY
and
MTI MICROFUEL CELLS INC.
dated
September 19, 2003
STRATEGIC ALLIANCE AGREEMENT
This Strategic Alliance Agreement (this "Agreement"), dated as of September 19, 2003 (the "Effective Date"), is made and entered into by and between The Gillette Company, a Delaware corporation ("Gillette"), and MTI MicroFuel Cells Inc., a Delaware corporation ("MTI"). Each of Gillette and MTI is referred to in this Agreement, from time to time, as a "Party" or, collectively, the "Parties".
W I T N E S S E T H :
WHEREAS, Gillette is a leader in inventing, manufacturing, marketing and distributing consumer products, including through its Duracell division a wide variety of batteries and energy cells;
WHEREAS, MTI is a leader in the design and development of direct methanol micro fuel cells for portable power applications;
WHEREAS, the Parties wish to enter into a strategic relationship to develop and Commercialize an energy solution for widely used, mass market, high volume, hand-held consumer devices, such as personal digital assistants (commonly referred to as PDAs), cell phones, digital cameras, portable CD players and portable DVD players, which energy solution is based on a DMFC (as defined herein) with an FCA that generates low power [*] and is used in connection with FRs (as defined herein) [*] appropriate for such mass market devices (a "DMFC Solution");
WHEREAS, one of the purposes of this Agreement is to allow Gillette to create a proprietary intellectual property position with respect to FRs; and
WHEREAS, in connection with the strategic relationship described above, MTI has requested that Gillette make an equity investment in MTI, and Gillette has agreed to make such an investment.
NOW THEREFORE, in consideration of the above stated premises and the mutual covenants and agreements set forth below, the Parties hereby agree as follows:
- DEFINITIONS
Defined terms used in this Agreement, as indicated by the use of initial capitalization, shall have the meanings set forth in Exhibit A. Defined terms that do not appear in Exhibit A shall have the meanings ascribed to them upon their first occurrence herein.
__________________________
- Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange Commission (the "Commission"). The omitted portions, marked by "[*]", have been filed separately with the Commission.
- PRODUCT DEVELOPMENT
Pursuant to the covenants listed below and in accordance with each Work Plan established hereunder, the Parties hereby agree to use Commercially Reasonable Efforts to develop one or more DMFC Solutions.
Generally. Pursuant to the terms and conditions set forth in this Agreement, the Parties agree to develop one or more DMFC Solutions for one or more OEM Applications. The processes for identifying the Initial OEM Application for which a DMFC Solution will be developed hereunder and each Additional OEM Application for which a DMFC Solution will be developed hereunder are set forth in Section 2.2 and Section 2.7, respectively. The development of each DMFC Solution hereunder shall be governed by a Work Plan and facilitated by the Steering Committee. The Work Plan for the DMFC Solution for the Initial OEM Application (the "Initial Work Plan") is set forth on Exhibit B to this Agreement. As set forth more specifically herein and in the applicable Work Plan, each Party has agreed as follows with respect to the development of DMFC Solutions:
184359
|
Mechanical
As referenced in this Strategic Alliance Agreement:
MECHANICAL TECHNOLOGY INC. –
R&G DRAFT
EX-10 3 exb10119.htm MECHANICAL TECHNOLOGY INC. - EXHIBIT 10.119 STRATEGIC ALLIANCE AGREEMENT
Exhibit 10.119
STRATEGIC ALLIANCE AGREEMENT
between
THE GILLETTE COMPANY
and
MTI MICROFUEL CELLS INC.
dated
September 19, 2003
STRATEGIC ALLIANCE AGREEMENT
This _____________
dt 1453781
;
Wilmer Cutler
As referenced in this Strategic Alliance Agreement:
Wilmer, Cutler – Attn: Catherine Hill, Esq.
with a copy, which shall not constitute notice hereunder, sent to:
Wilmer, Cutler & Pickering
2445 M Street, NW
Washington, DC 20037
(202) 663-6967 phone
(202)
dt 32236
;
| The Gillette Company;
MTI Microfuel Cells Inc.
|
Preview
Full Doc
 | 2001 |
Most Favored Supplier And Alliance Agreement
Most Favored Supplier And Alliance Agreement (97K)
Doc #246917: Click preview link for longer preview.
MOST FAVORED SUPPLIER
AND
ALLIANCE AGREEMENT
AMONG
SCHLUMBERGER OILFIELD HOLDINGS LIMITED
SCHLUMBERGER TECHNOLOGY CORPORATION
AND
HANOVER COMPRESSION LIMITED PARTNERSHIP
Dated
August 31, 2001 {PAGE}
TABLE OF CONTENTS
{TABLE} {CAPTION} Page ---- {S} {C} ARTICLE I PURPOSE OF STRATEGIC ALLIANCE....................................................................... 2 1.1 Mission Statement............................................................................ 2 1.2 Alliance Objectives.......................................................................... 2 1.3 Alliance Goals............................................................................... 2
ARTICLE II OPERATION OF THE STRATEGIC ALLIANCE................................................................ 3 2.1 Management of Activities under the Strategic Alliance........................................ 3 2.2 Meetings of the Management Committee......................................................... 3 2.3 Responsibilities of the Management Committee................................................. 3 2.4 No Solicitation of Employees................................................................. 5
ARTICLE III RESPONSIBILITIES OF THE PARTIES................................................................... 6 3.1 Joint Responsibilities of Hanover and Schlumberger........................................... 6 3.2 Pursuing Designated Projects................................................................. 7 3.3 Business Cooperation in Schlumberger GeoMarkets.............................................. 8 3.4 Most Favored Supplier Status................................................................. 9 3.5 Automation Systems Alignment/Licensing....................................................... 11 3.6 Business Process Alignment/ISO Certification/Schlumberger QHSE Standards..................... 12
ARTICLE IV TERM AND PAYMENT................................................................................... 12 4.1 Consideration................................................................................ 12 4.2 Initial Term................................................................................. 13 4.3 Additional Terms............................................................................. 13 4.4 Termination for Default or Otherwise......................................................... 13 4.5 Registration Rights Agreement................................................................ 14
ARTICLE V REPRESENTATIONS AND WARRANTIES...................................................................... 14 5.1 Representations and Warranties of the Parties................................................ 14 5.2 Additional Representation of Schlumberger.................................................... 14 5.3 Survival of Representations and Warranties................................................... 15
ARTICLE VI TAXES.............................................................................................. 15 6.1 Taxes........................................................................................ 15 6.2 Withholding Taxes............................................................................ 15 6.3 Sales and Value Added Tax.................................................................... 16 6.4 Definitions.................................................................................. 16
ARTICLE VII INDEMNIFICATION AND INSURANCE..................................................................... 16 7.1 INDEMNIFICATION.............................................................................. 16 7.2 Insurance.................................................................................... 17 7.3 Survival..................................................................................... 17 {/TABLE}
i {PAGE}
TABLE OF CONTENTS (continued)
{TABLE} {CAPTION} Page ---- {S} {C} ARTICLE VIII PROPRIETARY INFORMATION.......................................................................... 17 8.1 Proprietary Information...................................................................... 17 8.2 Disclosure................................................................................... 17 8.3 Covenant..................................................................................... 17 8.4 Authorization................................................................................ 18 8.5 Right to Disclose............................................................................ 18 8.6 No Rights to Proprietary Information......................................................... 18 8.7 Legal Process................................................................................ 18 8.8 Survival..................................................................................... 19
ARTICLE IX INVENTIONS AND DISCOVERIES......................................................................... 19 9.1 Single Party Inventions and Discoveries...................................................... 19 9.2 Joint Inventions and Discoveries............................................................. 19
ARTICLE X NON-COMPETITION..................................................................................... 20
ARTICLE XI WITHHOLDING OF INTEREST PAYMENTS................................................................... 20
ARTICLE XII MISCELLANEOUS..................................................................................... 21 12.1 Legal Relationship of Parties................................................................ 21 12.2 Non-Exclusivity.............................................................................. 21 12.3 Compliance With Laws......................................................................... 21 12.4 Assignment................................................................................... 21 12.5 Publicity.................................................................................... 21 12.6 Entire Agreement............................................................................. 22 12.7 Notices...................................................................................... 22 12.8 Forum; Waiver of Jury Trial.................................................................. 23 12.9 Limitation on Damages........................................................................ 23 12.10 Costs and Expenses........................................................................... 23 12.11 Counterparts................................................................................. 24 12.12 Severability................................................................................. 24 12.13 Waiver....................................................................................... 24 12.14 Compliance with FCPA......................................................................... 24 12.15 Further Assurances........................................................................... 24 12.16 Applicable Law............................................................................... 24 {/TABLE}
ii {PAGE}
MOST FAVORED SUPPLIER AND ALLIANCE AGREEMENT
This MOST FAVORED SUPPLIER AND ALLIANCE AGREEMENT (this "Agreement") is --------- entered into and effective this 31st day of August, 2001 by and among SCHLUMBERGER OILFIELD HOLDINGS LIMITED, a British Virgin Islands corporation ("SOHL"), SCHLUMBERGER TECHNOLOGY CORPORATION, a Texas corporation ("STC" and ---- --- together with SOHL, "Schlumberger"); and HANOVER COMPRESSION LIMITED ------------ PARTNERSHIP, a Delaware limited partnership, together with its affiliates ("Hanover"). In addition, CAMCO INTERNATIONAL INC., a Delaware corporation, and ------- HANOVER COMPRESSOR COMPANY, a Delaware corporation, each join in making this Agreement for the limited purposes described above such entity's name on the signature pages hereto. Schlumberger and Hanover are sometimes referred to individually as a "Party" and collectively as the "Parties." To the extent this ----- ------- Agreement refers to rights or obligations of Schlumberger within the United States, the term "Schlumberger" shall mean only STC and to the extent that this ------------ Agreement refers to rights and obligations of Schlumberger outside the United States, the term "Schlumberger" shall mean only SOHL. ------------
RECITALS
WHEREAS, Schlumberger is a respected developer and worldwide provider of drilling, completion, production and project management services, together with specialized know-how, ideas and technology relating thereto, and presently possesses the expertise and business contacts to market and develop such services on a worldwide basis;
WHEREAS, Hanover is a respected worldwide provider of full service natural gas compression on a rental, contract compression, maintenance and acquisition leaseback basis, including the servicing, financing, fabrication and equipment for contract natural gas, oil and water handling applications, power generation, pump systems and gas measurement;
WHEREAS, Schlumberger and Hanover have agreed to enter into a strategic relationship (the "Strategic Alliance") and, subject to the terms hereof, to ------------------ align their respective resources for the purpose of enhancing the Parties ability to, individually or collectively, provide best value solutions in agreed upon sectors of the oil and gas industry worldwide;
WHEREAS, Schlumberger and Hanover have agreed that Hanover shall enter into a most favored supplier relationship pursuant to which, subject to the terms hereof, Hanover shall be Schlumberger's most favored supplier (the "MFS --- Relationship") with respect to all of Schlumberger's and it affiliates' gas ------------ compression and certain oilfield surface production requirements; and
WHEREAS, Schlumberger and Hanover desire to enter into such Strategic Alliance and MFS Relationship upon the terms and conditions set forth in this Agreement. {PAGE}
AGREEMENT
NOW, THEREFORE, in consideration of the premises, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Schlumberger and Hanover agree as follows:
ARTICLE I
PURPOSE OF STRATEGIC ALLIANCE
1.1 Mission Statement. It is the mission of the Parties to align their respective goals and resources whenever mutually determined to be consistent with their common commercial interests for the purpose of fostering and maintaining a dynamic and enduring collaborative relationship which will enhance their ability to meet the needs of the oil and gas industry worldwide for best value solutions utilizing their complimentary alliance services.
1.2 Alliance Objectives. The purpose of the Strategic Alliance is for Schlumberger and Hanover to work together with the goal of creating a comprehensive, mutually satisfactory, long-term relationship to:
(a) Enhance Schlumberger's and Hanover's ability to provide coordinated services to customers.
(b) Exploit common areas of potential business growth through operational and technical synergies.
(c) Assist Hanover in penetrating and establishing a presence in certain new international markets.
(d) Develop solutions which result in lower lease operating expense to clients through enhanced production and more efficient equipment and capital utilization.
1.3 Alliance Goals. The intent of the Parties in entering the Strategic Alliance is to develop, support and continuously improve the way Schlumberger and Hanover conduct business together when mutually determined to be appropriate by establishing and meeting the following goals:
(a) Schlumberger and Hanover will be committed to conducting their activities under the Strategic Alliance in a safe and environmentally responsible manner.
(b) Schlumberger and Hanover will develop an in-depth understanding of their respective needs and capabilities in order to continuously improve the Strategic Alliance and the services they provide under the Strategic Alliance.
(c) Schlumberger and Hanover will establish common success assessment systems for their performance under the Strategic Alliance.
246917
|
Enron
As referenced in this Most Favored Supplier And Alliance Agreement:
Enron Corp. – the management and
production thereof, together with any natural evolution thereof. The Parties
agree that companies whose primary businesses are midstream (e.g. El Paso,
Dynergy, Reliant Energy, Kinder Morgan, Enron Corp. and The Williams Companies
Inc.), shall not be deemed a competitor of Schlumberger's Oilfield Services
Businesses; or
13
{PAGE}
(g) immediately by Schlumberger if any Primary Competitor, or _____________
dt 1336276
;
Hanover
As referenced in this Most Favored Supplier And Alliance Agreement:
HANOVER COMPRESSION LIMITED PARTNERSHIP
– AGREEMENT
{TEXT}
{PAGE}
Exhibit 99.4
EXECUTION COPY
MOST FAVORED SUPPLIER
AND
ALLIANCE AGREEMENT
AMONG
SCHLUMBERGER OILFIELD HOLDINGS LIMITED
SCHLUMBERGER TECHNOLOGY CORPORATION
AND
HANOVER COMPRESSION LIMITED PARTNERSHIP
Dated
August 31, 2001
{PAGE}
TABLE OF CONTENTS
{TABLE}
{CAPTION}
Page
----
{S} {C}
ARTICLE I PURPOSE OF STRATEGIC ALLIANCE....................................................................... 2
1.1 _____________
HANOVER COMPRESSION LIMITED
------------
PARTNERSHIP, – SCHLUMBERGER OILFIELD HOLDINGS LIMITED, a British Virgin Islands corporation
("SOHL"), SCHLUMBERGER TECHNOLOGY CORPORATION, a Texas corporation ("STC" and
---- ---
together with SOHL, "Schlumberger"); and HANOVER COMPRESSION LIMITED
------------
PARTNERSHIP, a Delaware limited partnership, together with its affiliates
("Hanover"). In addition, CAMCO INTERNATIONAL INC., a Delaware corporation, and
-------
HANOVER COMPRESSOR COMPANY, a _____________
Hanover Compression Limited Partnership
– 400
Austin, Texas 78746
Attention: Brian P. Fenske, Esq.
Facsimile: (512) 457-7001
Telephone: (512) 457-7145
If to Hanover, addressed as follows:
Hanover Compression Limited Partnership
12001 North Houston Rosslyn
Houston, Texas 77806
Attention: William S. Goldberg
Telephone: (281) 447-8787
Facsimile: (281) 447-0821
23
{PAGE}
with _____________
HANOVER COMPRESSION LIMITED PARTNERSHIP
– year first above written.
SCHLUMBERGER OILFIELD HOLDINGS LIMITED
By:___________________________________________
Name:_________________________________________
Title:________________________________________
SCHLUMBERGER TECHNOLOGY CORPORATION
By:___________________________________________
Name:_________________________________________
Title:________________________________________
HANOVER COMPRESSION LIMITED PARTNERSHIP
By:___________________________________________
Name: Michael J. McGhan
Title: President and Chief Executive Officer
i
{PAGE}
Each of the following have caused this Most _____________
dt 100598
;
HCC
As referenced in this Most Favored Supplier And Alliance Agreement:
HANOVER COMPRESSOR – partnership, together with its affiliates
("Hanover"). In addition, CAMCO INTERNATIONAL INC., a Delaware corporation, and
-------
HANOVER COMPRESSOR COMPANY, a Delaware corporation, each join in making this
Agreement for the limited purposes described _____________
Hanover Compressor – i) SOHL $6,281,200 in cash and 114,424 shares of common stock of
Hanover Compressor Company, a Delaware corporation and the parent of Hanover
("Parent"), and (ii) STC $2,826, _____________
HANOVER COMPRESSOR – which the undersigned will be
parties.
CAMCO INTERNATIONAL INC.
By:__________________________________________
Name:________________________________________
Title:_______________________________________
HANOVER COMPRESSOR COMPANY
By:__________________________________________
Name: Michael J. McGhan
Title: President and Chief Executive Officer
ii
{/TEXT}
{/ _____________
dt 75040
;
|
Schlumberger
As referenced in this Most Favored Supplier And Alliance Agreement:
SCHLUMBERGER TECHNOLOGY CORP – DESCRIPTION}SUPPLIED AND ALLIANCE AGREEMENT
{TEXT}
{PAGE}
Exhibit 99.4
EXECUTION COPY
MOST FAVORED SUPPLIER
AND
ALLIANCE AGREEMENT
AMONG
SCHLUMBERGER OILFIELD HOLDINGS LIMITED
SCHLUMBERGER TECHNOLOGY CORP ORATION
AND
HANOVER COMPRESSION LIMITED PARTNERSHIP
Dated
August 31, 2001
{PAGE}
TABLE OF CONTENTS
{TABLE}
{CAPTION}
Page
----
{S} {C}
ARTICLE I PURPOSE OF _____________
SCHLUMBERGER TECHNOLOGY CORP – entered into and effective this 31st day of August, 2001 by and among
SCHLUMBERGER OILFIELD HOLDINGS LIMITED, a British Virgin Islands corporation
("SOHL"), SCHLUMBERGER TECHNOLOGY CORP ORATION, a Texas corporation ("STC" and
---- ---
together with SOHL, "Schlumberger"); and HANOVER COMPRESSION LIMITED
------------
PARTNERSHIP, a Delaware limited partnership, together with its affiliates
(" _____________
SCHLUMBERGER TECHNOLOGY CORP – All notices
and other communications provided for in this Agreement shall be addressed as
follows:
22
{PAGE}
If to STC, addressed as follows:
SCHLUMBERGER TECHNOLOGY CORP ORATION
300 Schlumberger Drive MD:23
Sugar Land, Texas 77476
Attention: General Counsel
Telephone: (281) 285-8414
Facsimile: (281) 285-6952
with a _____________
SCHLUMBERGER TECHNOLOGY CORP – duly authorized representatives effective as of the date and
year first above written.
SCHLUMBERGER OILFIELD HOLDINGS LIMITED
By:___________________________________________
Name:_________________________________________
Title:________________________________________
SCHLUMBERGER TECHNOLOGY CORP ORATION
By:___________________________________________
Name:_________________________________________
Title:________________________________________
HANOVER COMPRESSION LIMITED PARTNERSHIP
By:___________________________________________
Name: Michael J. McGhan
Title: President and Chief Executive Officer
_____________
dt 99937
;
More... |
Preview
Full Doc
 | 2004 |
Strategic Alliance Agreement
Strategic Alliance Agreement (186K)
Doc #282568: Click preview link for longer preview.
STRATEGIC ALLIANCE AGREEMENT
This STRATEGIC ALLIANCE AGREEMENT (the "Agreement"), having a date of April 1, 2004, is made by and between, on the one hand, F. HOFFMANN-LA ROCHE LTD, a Swiss corporation, having its principal place of business at Grenzacherstrasse 124, CH-4070, Basel, Switzerland and HOFFMANN-LA ROCHE INC., a New Jersey corporation, having its principal place of business at 340 Kingsland Street, Nutley, New Jersey 07110 (collectively "Roche") and, on the other hand, ARQULE, INC., a Delaware corporation, having its principal place of business at 19 Presidential Way, Woburn, Massachusetts 01801-5140 ("ArQule").
INTRODUCTION
1. ArQule has a development program relating to pharmaceutical compounds for the treatment of oncological diseases based on its E2F1 technology and associated compounds (the "ArQule Program"), and owns related intellectual property rights.
2. Roche has expertise in the research, development, manufacture and commercialization of pharmaceutical products.
3. Roche desires to secure rights to further develop and commercialize products developed and to be developed pursuant to the ArQule Program.
4. In consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ArQule and Roche agree as follows:
ARTICLE 1 DEFINITIONS
As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings:
[*]=CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. OMITTED TEXT IS INDICATED BY A "*".
- 1 - {PAGE}
1.1 "Adjusted Gross Sales" means the amount of gross sales of a Product invoiced by Roche, its Affiliates and its sublicensees to independent third parties less deductions for returns and return reserves (such reserves consistent with International Financial Reporting Standards) (including allowances actually given for spoiled, damaged, out-dated, rejected or returned Product sold, withdrawals and recalls), rebates to the extent consistently and reasonably applied by Roche to its products (price reductions, rebates to social and welfare systems, charge backs and charge back reserves (such reserves consistent with International Financial Reporting Standards), cash sales incentives (but only to the extent it is a sales related deduction which is accounted for within Roche on a product-by-product basis)), government mandated rebates and similar types of rebates (e.g., P.P.R.S. Medicaid, each as consistently and reasonably applied by Roche to its products), volume (quantity) discounts, each as consistently and reasonably applied by Roche to its products, and taxes (value added or sales taxes, government mandated exceptional taxes and other taxes directly linked to the gross sales amount), it being understood that income and capital gains taxes are not the type of taxes contemplated as a deduction in this definition of Adjusted Gross Sales. Notwithstanding the foregoing, amounts received by Roche, its Affiliates and sublicensees for the sale of Product among Roche, its Affiliates or sublicensees for resale shall not be included in the computation of Adjusted Gross Sales.
1.2 "Adverse Drug Reaction" and "Adverse Event" shall have the meaning given at 21 C.F.R. 314.80 or 21 C.F.R. 312.32, as applicable, and in the ICH guidelines. For purposes of this Agreement, "ICH guidelines" means the E2A ICH Harmonized Tripartite Guideline: Clinical Safety Data Management - Definitions and Standards for Expedited Reporting (as currently in effect and adopted by the relevant regulatory agency).
1.3 "Affiliate" means (a) a business entity which owns, directly or indirectly, more than fifty percent (50%) of the voting shares or other means of control of a Party; or (b) a business entity in which more than fifty percent (50%) of the voting shares or other means of control are owned by a Party, either directly or indirectly; or (c) a business entity, the majority ownership of which is directly or indirectly common to the majority ownership of a Party. Anything to the contrary in this paragraph notwithstanding, Genentech, Inc., a Delaware corporation, and Chugai Pharmaceutical Co., Ltd., a Japanese corporation, (each, a "Roche Entity"), shall not be deemed an Affiliate of Roche unless Roche provides written notice to ArQule of its desire to include a particular Roche Entity as an Affiliate of Roche and such Roche Entity otherwise meets the definition of an Affiliate. Notwithstanding such written notice, if any Roche Entity does not agree to be bound by the terms and conditions of this Agreement, then such Roche Entity shall have none of the rights and obligations of an Affiliate of Roche under this Agreement, and such Roche Entity shall be treated as a Third Party under this Agreement and, accordingly, Roche may not grant a sublicense to such Roche Entity except as permitted by Section 2.3 hereof. Notwithstanding the preceding
- 2 - {PAGE}
provisions, once an entity ceases to be an Affiliate, then such entity shall, without any further action, cease to have any rights, including license and sublicense rights, under this Agreement that it has by reason of being an Affiliate.
1.4 "Agreement Term" means the term of this Agreement, more fully described in Section 17.2.
1.5 "ArQule Know-How" means all Know-How that ArQule owns, or otherwise has the right to grant as part of and pertinent to the License that may be granted herein, during the Agreement Term.
1.6 "ArQule Patent Rights" means all Patent Rights that ArQule owns or otherwise controls and has the right to grant as part of the License that may be granted herein during the Agreement Term. As of the date set forth in the first paragraph of this Agreement, the ArQule Patent Rights are as specified in Schedule 1.
1.7 "ArQule Program" has the meaning given in the first paragraph of the Introduction of this Agreement.
1.8 "Backup Compound" means, as of the Option Exercise, any analog of the Primary Compound and any other compound developed by ArQule that has been screened for regulation of the E2F1 protein prior to the Effective Date or as part of the Strategic Alliance, and as a direct result of such screening has been determined to modulate E2F1 in cancer cells, directly leading to apoptosis.
1.9 "Bioequivalent Product" means, with respect to a given Product sold in a given country of the Territory by Roche, its Affiliate or sublicensee, a product sold by a Third Party in such country containing the same compound (or an acid, salt or ester thereof) as an Optioned Compound.
1.10 "Clinical Candidate" means, subject to Section 4.3(a), as of or within * following the date of the Option Exercise, a Backup Compound that has commenced * studies.
1.11 "Combination Product" means any product containing both a pharmaceutically active agent that causes it to be considered a Product and one or more other pharmaceutically active agents that are not Products.
1.12 "Compound Evaluation Report" shall have the meaning given in Section 9.3.
1.13 "Cover" (including the variations such as "Covered", "Coverage" or "Covering") shall mean that the making, using, offering for sale, selling or importing of a given compound or product would infringe a claim of a Patent Right in the absence of a license under such Patent Right. The determination of whether a compound or product is Covered by a particular Patent Right shall be made on a country-by-country basis. In the event of a disagreement between the Parties as to whether a compound or product is Covered by a particular Valid Claim, the
- 3 - {PAGE}
Parties shall refer such disagreement pursuant to the dispute resolution process of Section 18.1.
1.14 "Effective Date" shall have the meaning given in Section 17.1(a).
1.15 "End of Phase 1" means the date of completion of a particular Phase 1 clinical trial.
1.16 "End of Phase 2" means the date of completion of a particular Phase 2 or Phase 2a clinical trial.
1.17 "EU Launch" means a Launch in any country in Europe.
1.18 "EU NDA Filing" means an application for marketing authorization filed in the European Union for a given Product and a given Indication.
1.19 "Europe" means the United Kingdom, Germany, Italy, France, and Spain.
1.20 "FDA" means the US Food and Drug Administration.
1.21 "Field" means only all Indications. For the avoidance of doubt, the Field does not include Specifically Excluded Areas.
1.22 "IND" means an Investigational New Drug Application filed with the FDA, or the foreign equivalent, for human clinical testing of a drug.
1.23 "Indication" means any therapeutic indication for human cancer.
1.24 "Initiation of Phase 1" means the date that a human is first dosed with a Product in a Phase 1 clinical trial.
1.25 "Initiation of Phase 2" means the date that a human is first dosed with a Product in a Phase 2 clinical trial. In the event a Phase 1b clinical trial and a Phase 2 clinical trial constitute component parts of a combined trial, "Initiation of Phase 2" means the formal commencement date pursuant to the applicable protocol of the Phase 2 clinical trial component part.
1.26 "Initiation of Phase 3" means the date that a human is first dosed with a Product in a Phase 3 clinical trial.
1.27 "Invention" means an invention that is conceived or reduced to practice in the conduct of the Strategic Alliance.
1.28 "Invention Priority Application" means a patent application that can be cited as a priority document for a patent filing.
1.29 "Joint Patent Rights" means all Patent Rights that ArQule and Roche jointly own, or otherwise jointly have the right to grant as part of the licenses herein, during the Agreement Term.
- 4 - {PAGE}
1.30 "Joint R&D Committee" has the meaning given in Section 8.2.
1.31 "Know-How" means data, knowledge and information, including materials, samples, chemical manufacturing data, toxicological data, pharmacological data, preclinical data, assays, platforms, formulations, specifications, quality control testing data, that are necessary for the discovery, manufacture, development or commercialization of Optioned Compounds or Products in the Territory.
1.32 "Launch" means, with respect to a Product in a country of the Territory, the date of the first commercial sale to a Third Party by Roche, its Affiliate or its sublicensee of the given Product in the given country.
1.33 "License" has the meaning given in Section 2.1(a).
1.34 "License Rights Maintenance Fees" means the payments by Roche to ArQule pursuant to Section 4.4 hereof.
1.35 "Major Indication" means an Indication for any one or more of the following types of human cancer: *.
1.36 "Major Market Countries" means the US, Canada, Japan and any country in Europe.
1.37 "Net Sales" means:
(a) for the US, the amount calculated by subtracting from the amount of Adjusted Gross Sales a lump sum deduction of * percent (*%) of Adjusted Gross Sales in lieu of those sales related deductions which are not accounted for within Roche on a product by product basis (e.g., outward freight, postage charges, transportation insurance, packaging materials for dispatch of goods, custom duties, bad debt, and legal discounts granted later than at the time of invoicing);
(b) for the ROW Territory, the amount calculated by subtracting from the amount of Adjusted Gross Sales a lump sum deduction of * percent (*%) of Adjusted Gross Sales in lieu of those sales related deductions which are not accounted for within Roche on a product by product basis (e.g., outward freight, postage charges, transportation insurance, packaging materials for dispatch of goods, custom duties, bad debt, and legal discounts granted later than at the time of invoicing).
Notwithstanding the foregoing, amounts received by Roche, its Affiliates and sublicensees for the sale of Product among Roche, its Affiliates or sublicensees for resale shall not be included in the computation of Net Sales.
1.38 "Option Exercise" has the meaning given in Section 2.1(a).
- 5 - {PAGE}
1.39 "Option Exercise Period" means the period beginning on the last day of the Option Term, and ending * calendar days thereafter.
1.40 "Option Term" means the period commencing on the Effective Date and ending on the date that is the earlier of the Option Trigger Date and *, except as extended pursuant to Section 4.5.
1.41 "Option Trigger Date" means the date on which ArQule has delivered to Roche the Compound Evaluation Report.
1.42 "Optioned Compounds" means the Primary Compound, the Clinical Candidates and, if Roche makes the payment set forth in Section 4.3(b), then also the Potential Optioned Compounds.
1.43 "Other Indication" means any Indication that is not a Major Indication.
1.44 "Party" means Roche or ArQule, and "Parties" means Roche and ArQule.
1.45 "Patent Rights" means all rights under any patent or patent application, in any country of the Territory, including any patents issuing on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division, continuation or continuation-in-part of any of the foregoing, Covering a Product or an Optioned Compound in the Territory.
1.46 "Phase 1" means the first phase of human clinical trials of a drug required by the FDA to gain evidence of safety in patients, as described in 21 C.F.R. Part 312, as it may be amended.
1.47 "Phase 1a" means the currently ongoing Phase 1 trial of the Primary Compound governed by the IND filed on July 7, 2003.
1.48 "Phase 1b" means a Phase 1 study of the Primary Compound (in a combination protocol) subsequent to Phase 1a.
1.49 "Phase 2" means the second phase of human clinical trials of a drug required by the FDA to gain evidence of efficacy in the target population for an Indication, determine optimal dosage, and obtain expanded evidence of safety for Product(s), as described in 21 C.F.R. Part 312, as it may be amended.
1.50 "Phase 2a" means the first set of exposure response studies in patients in Phase 2 trials (conducted in a Major Market Country) collectively designed to demonstrate clinical proof of concept. These studies shall incorporate early stopping rules, where feasible and appropriate.
1.51 "Phase 3" means the third phase of human clinical trials of a drug required by the FDA to gain evidence of efficacy in the target population for an Indication and
- 6 - {PAGE}
obtain expanded evidence of safety for Product(s), as described in 21 C.F.R. Part 312, as it may be amended.
1.52 "Potential Optioned Compounds" means, as of the date of the Option Exercise, those Backup Compounds which have not been selected as Clinical Candidates.
1.53 "Primary Compound" means the compound known as ARQ 501.
1.54 "Primary Compound Trials" means at least * clinical trials with respect to the Primary Compound, of which (a) * shall be in *, (b) * shall be in * as a * and (c) * shall be in * either as a * or as a * protocol (to be determined by the Joint R&D Committee), in each case for tumor types to be determined by the Joint R&D Committee.
1.55 "Product" means any and all products for use in the Field that include, in whole or as a component thereof, an Optioned Compound. "Product" shall also include any and all products that include, in whole or as a component thereof, any Optioned Compound to which Roche has acquired a license pursuant to Section 2.1(b).
1.56 "Publishing Party" shall have the meaning set forth in Section 16.4(a).
1.57 "Reasonable Diligence" means the same standard of effort as used by the Parties, or in any case not less than common in the industry taken as a whole for similarly situated companies, for the activities to be undertaken pursuant to this Agreement, including, in the case of Roche, activities relating to development, clinical testing, manufacturing, marketing and sale, with respect to a product which (i) is intended to receive approval from FDA or another regulatory agency in Major Market Countries and (ii) has similar potential for treatment of an Indication as do the Optioned Compounds, taking into account scientific, business, marketing and return on investment considerations. It is understood that such compound potential may change from time to time based upon changing scientific, business, marketing and return on investment considerations. The Parties also acknowledge that, even within the Major Market Countries, Roche and its Affiliates do not always seek to market their own products in every such country or seek to obtain regulatory approval in every such country or for every potential indication or every compound that has potential for an indication. As a result, the exercise by Roche of Reasonable Diligence is to be determined by judging its efforts taken as a whole.
1.58 "Research Plan" means the plan of research and development attached as Schedule 2, developed by the Parties, outlining the work expected to be performed by ArQule as part of the Strategic Alliance, as such plan may be updated from time to time as provided in this Agreement.
1.59 "Regulatory Approval" means any approvals (including pricing and reimbursement approvals), licenses, registrations or authorizations of any national or international or local regulatory authority, department, bureau or other
- 7 - {PAGE}
governmental entity, necessary for the manufacture, marketing and sale of a Product in a regulatory jurisdiction in the Territory.
1.60 "Roche Patent Rights" means all Patent Rights that Roche owns or otherwise controls and has the right to grant as part of the licenses herein, during the Agreement Term.
1.61 "ROW Territory" means all countries and territories in the world other than the US.
1.62 "Serious Adverse Drug Reaction" and "Serious Adverse Event" shall have the meaning given at 21 C.F.R. 314.80 or 21 C.F.R. 312.32, as applicable, and the ICH guidelines.
1.63 "Specifically Excluded Areas" means (i) the *, and (ii) the *.
1.64 "Strategic Alliance" means discovery and development by ArQule of pharmaceutical compounds in the Field during the Agreement Term and development and commercialization of such compounds by Roche and ArQule pursuant to this Agreement.
1.65 "Territory" means all countries and territories in the world, provided however that in the event Roche exercises its right of termination pursuant to Section 17.4(c) with respect to any country or countries, such country or countries shall be excluded from the definition of "Territory."
1.66 "Third Party" means a person or entity other than (i) ArQule or any of its Affiliates or (ii) Roche or any of its Affiliates.
1.67 "US" means the United States of America and its possessions and territories, including Puerto Rico.
1.68 "US Launch" means Launch in the US.
1.69 "US NDA" means a New Drug Application filed with the FDA for a drug.
1.70 "US NDA Filing" means for a given Product, the date that a US NDA is filed with the FDA for such Product for an Indication.
1.71 "Valid Claim" means a claim in any (i) unexpired and issued patent right that has not been (x) held permanently revoked, unenforceable or invalid by a final unappealable decision of a court or government agency of competent jurisdiction over such claim or (y) admitted to be invalid or unenforceable through disclaimers, consent decrees or otherwise, or (ii) pending patent application that has been on file with the applicable patent office for no more than ten (10) years and for which there has been reasonably consistent activity to advance to issuance of a patent.
- 8 - {PAGE}
ARTICLE 2 GRANTS
2.1 Grants.
(a) Subject to the terms and conditions of this Agreement, commencing on the Effective Date and ending at the conclusion of the Option Exercise Period, Roche shall have the right with respect to the Products to exercise an option ("Option Exercise") to obtain a sole and exclusive license, including the right to grant sublicenses in accordance with Section 2.3, under the ArQule Patent Rights and Joint Patent Rights, and a non-exclusive license to use the ArQule Know-How, in each case solely to make, use, offer for sale, sell and import the Products in the Territory for use in the Field (the "License").
(b) If Roche has effected the Option Exercise, and, within * after the date of Option Exercise, Roche has delivered a written notice to ArQule designating a particular Optioned Compound as subject to this Section 2.1(b), then, subject to the terms and conditions of this Agreement, Roche shall have, with respect to such designated Optioned Compound and its associated Products, for no further consideration, a sole and exclusive license, including the right to grant sublicenses in accordance with Section 2.3, under the ArQule Patent Rights, and a non-exclusive license to use the ArQule Know-How, in each case solely to make, use, offer for sale, sell and import such product in the Territory for use outside the Field (except that such licenses shall exclude Specifically Excluded Areas).
(c) The right of Roche to effect the Option Exercise shall be made by Roche giving ArQule written notice to such effect prior to the conclusion of the Option Exercise Period and making or having made payment to ArQule of (1) all research and development payments specified in Section 4.1, (2) either (i) the one-time payment specified in Section 4.3(a) or (ii) the one-time payment specified in Section 4.3(b), and (3) any of the License Rights Maintenance Fees due and payable pursuant to Section 4.4, or, subject to Section 8.2(f), if an event or events described in Section 4.4 which, but for having occurred prior to the date of Option Exercise, would have triggered the payment of such License Rights Maintenance Fee(s), the License Rights Maintenance Fee(s) associated with such event or events.
(d) If Roche exercises its right to obtain the License as provided in this Section 2.1, ArQule shall be deemed to have granted such License hereunder without any requirement for further action by or on behalf of either Party. For the avoidance of doubt, except as may be provided pursuant to Section 2.1(g), Roche shall have no license or other rights (except for the right to effect the Option Exercise) in or to any ArQule Patent Rights, ArQule Know-How or Optioned Compound unless and until it effects the Option Exercise.
- 9 - {PAGE}
(e) From and after the Option Exercise, Roche shall be responsible for and pay all costs and expenses relating to the continued development of Products, including obtaining all Regulatory Approvals with respect thereto.
(f) Except as expressly provided in Sections 2.1(b) and 2.1(h), nothing in this Agreement grants to Roche any option, right or license to use ArQule Know-How or ArQule Patent Rights for any purpose other than to make, use, offer for sale, sell and import Products in the Territory for use in the Field. Further, except as expressly provided in this Agreement to the contrary, nothing in this Agreement shall limit the right of ArQule to use ArQule Know-How or ArQule Patent Rights for any purpose not related to the making, using, offering for sale, selling or importing of Products in the Territory for use in the Field, including without limitation Potential Optioned Compounds.
(g) In the event that ArQule provides Roche with any compound or other material (including any Optioned Compound or Potential Optioned Compound) prior to the Option Exercise, Roche shall have the right to use such compound or other material solely for the purpose of evaluating whether to effect the Option Exercise. The foregoing right shall not include the right to grant sublicenses, and such right shall expire upon the earlier of the Option Exercise, if any, and the expiration of the Option Term.
(h) In the event that, after Roche has exercised its option pursuant to Section 2.1(a) but prior to the end of the Agreement Term, ArQule wishes to license to any Third Party any ArQule Patent Rights Covering any Optioned Compound (other than any Optioned Compound to which Roche has acquired a license pursuant to Section 2.1(b)) outside of the Field (other than for Specifically Excluded Areas) (the "Rights"), the following procedures must be followed and the following conditions must be satisfied before ArQule may license such Rights to a Third Party:
(i) ArQule shall, prior to entering into negotiations with any Third Party, deliver to Roche written notice of ArQule's interest in negotiating such a license;
(ii) ArQule shall not, unless Roche indicates otherwise in a written notice to ArQule to the contrary, participate in any negotiations with any Third Party for a period of * following such notice. If Roche provides the notice referred to in section 2.1(h)(iii), the * period referred to in the preceding sentence shall be extended to * following receipt by ArQule of the notice referred to in Section 2.1(h)(iii);
(iii) If, on or before the expiration of such * period, Roche provides to ArQule written notice of Roche's interest in negotiating a
- 10 - {PAGE}
license to the Rights, ArQule and Roche shall engage in negotiations in good faith, for a period not to exceed * from ArQule's receipt of the notice from Roche, to enter into a license agreement for the Rights. Nothing in this Section 2.1(h)(iii) shall require either Party to enter into any such license agreement; and
(iv) In the event Roche fails to provide to ArQule notice of Roche's interest in negotiating a license agreement within the * period referred to in Section 2.1(h)(ii), or in the event the Parties fail to enter into such a license agreement within the * period referred to in Section 2.1(h)(iii), ArQule shall be free to license the Rights to any Third Party on any terms and conditions.
2.2 ArQule's Rights to Grant Licenses to Third Parties. In the event that Roche declines or fails to exercise its right to obtain the License, ArQule shall be free to license or grant any rights to a Third Party with respect to any Potential Optioned Compound or Optioned Compound in the Field or otherwise.
2.3 Sublicense Rights.
(a) Subject to the restriction set forth in Section 2.3(b), the rights and licenses granted to Roche in the event of an Option Exercise shall include the right of Roche to grant written sublicenses to its Affiliates and Third Parties under such rights and licenses, in whole or in part, solely to the extent necessary to make, use, offer for sale, sell or import Products in the Territory for use in the Field. If Roche grants such a sublicense, Roche shall ensure that all of the applicable terms and conditions of this Agreement shall apply to the Affiliate or Third Party sublicensee to the same extent as they apply to Roche for all purposes. Roche assumes full responsibility for the performance of all obligations and observance of all terms so imposed on such Affiliate or Third Party sublicensee and shall itself account to ArQule for all payments due under this Agreement by reason of such sublicense.
(b) Notwithstanding Section 2.3(a), for so long as ArQule has a co-promotion right with respect to a Product, Roche shall not have the right to sublicense the rights granted to Roche in the event of an Option Exercise to any Third Party with respect to such Product in the US, except upon the prior written approval of ArQule, which approval may be granted or withheld by ArQule in its sole discretion.
(c) Any sublicense may, at the written election of ArQule in its sole discretion, continue in full force and effect after the termination (in whole or in part) of the underlying License granted herein to Roche, and all sublicenses shall contain a provision to this effect. Upon the License that will be granted herein to Roche in the event of an Option Exercise
- 11 - {PAGE}
becoming fully paid up pursuant to Section 17.2, any and all sublicenses granted by Roche similarly shall become fully paid up as to ArQule.
2.4 ArQule Co-Promotion Right. ArQule shall have the right to co-promote each Product in the US, on a Product-by-Product basis, as specified in this Section 2.4. For purposes of this Agreement, "co-promote" and "co-promotion" shall mean the marketing, promotion, detailing and advertisement of a Product by or on behalf of ArQule or any of its Affiliates under the relevant Regulatory Approvals and the then existing trademarks. * shall not * of a *. ArQule may exercise its co-promotion right with respect to each Product by giving written notice thereof to Roche at any time during the period commencing upon the Initiation of * for such Product and ending * following such date, provided that at the time of such exercise ArQule has an established sales force or has committed resources and funds to hire a sales force sufficient to meet ArQule's co-promotion obligations. Upon ArQule's exercise of its co-promotion right with respect to any Product, the Parties shall negotiate in good faith and enter into a written co-promotion agreement (the "Co-Promotion Agreement"). In addition to any other terms agreed to by the Parties, the Co-Promotion Agreement shall contain the terms set forth in Schedule 3 hereto.
2.5 Requirement to Divest. If Roche is required by a relevant government authority in a given country of the Territory to divest rights to an Optioned Compound and/or Product with respect to which Roche has not commenced * prior to the order to divest, then Roche shall use its Reasonable Diligence to obtain authority to fulfill such requirement by * in and to such Optioned Compound and/or Product in accordance with the transfer procedures specified in Section 17.6. If Roche is required by a relevant government authority in a given country of the Territory to divest rights to an Optioned Compound and/or Product with respect to which Roche has commenced * prior to the order to divest, then Roche shall * to other potential acquirers of such rights, including in bidding or other acquisition processes.
ARTICLE 3 DILIGENCE
3.1 Diligence.
(a) ArQule shall use Reasonable Diligence in proceeding with the development of the Optioned Compounds in the Field, except that ArQule's obligation hereunder shall expire upon the earlier of the Option Exercise, if any, and the expiration of the Option Term. From and after the Option Exercise, Roche shall use Reasonable Diligence in proceeding with the development of at least one Product, including obtaining required Regulatory Approvals, and manufacturing, marketing and selling such Product or Products in the Major Market Countries.
- 12 - {PAGE}
(b) If either Party believes in good faith that the other Party has failed to utilize Reasonable Diligence as required by this Section 3.1, then such Party may give the other Party written notice of such alleged failure, identifying the Optioned Compounds or Product (if known) and giving specific detailed reasons supporting such allegation. Within * following the other Party's receipt of any such notice ("Response Period"), the other Party shall have the right to provide such Party with a written response specifying, in reasonable detail, how it has used Reasonable Diligence as required hereby.
(c) If the other Party has failed to provide within the Response Period a written response, in reasonable detail, indicating the manner in which it is in compliance with its obligations under this Section 3.1 or in which it has remedied any breach thereof, or the other Party has failed within the Response Period to remedy any breach of its obligations under this Section 3.1, then the Party alleging failure of Reasonable Diligence shall have the right to terminate this Agreement upon written notice to such Party effective as of the end of the Response Period, in addition to any other rights it may have under this Agreement as a result of such breach.
(d) In the event of a dispute between the Parties with respect to whether either Party has complied with its obligation under this Section 3.1, then such dispute shall be resolved in accordance with Article 18. The consequences of any termination under this Section 3.1 are set forth in Section 17.6.
(e) Roche acknowledges that ArQule may subcontract, and is permitted to subcontract, ArQule's obligations under this Agreement. However, prior to entering into any material subcontracts, ArQule shall first solicit the advice and input of Roche with respect to such subcontract.
3.2 Non-Exclusive Remedy. The Parties confirm and agree that nothing in this Article 3 limits the obligations or rights of Roche or ArQule under this Agreement.
ARTICLE 4 PAYMENTS TO ARQULE
4.1 Research and Development Payments.
(a) Roche shall reimburse to ArQule a total of * dollars ($*) for the ArQule Program research and development costs and expenses incurred by ArQule on or before the end of the Option Term. These payments shall be non-refundable and non-creditable, and shall be due and payable, except as provided in Section 4.1(b), as follows:
(i) Within * after the Effective Date, a payment of * dollars ($*);
- 13 - {PAGE}
(ii) A payment of * dollars ($*) due and payable within 30 days after * and receipt of an invoice for such amount; and
(iii) Aggregate payments totaling $*, payable in * equal quarterly installments of $* per installment, each installment due and payable within * after (i) the first day of each calendar quarter and receipt of an invoice from ArQule, with the first such installment of $* to be due and payable within * after * and receipt of an invoice from ArQule for such amount.
(b) Notwithstanding Section 4.1(a), if Roche effects the Option Exercise, the entire amount of the payment otherwise due and not yet paid pursuant to Section 4.1(a) shall be immediately due and payable in full upon such exercise.
4.2 Decision. By the end of the Option Exercise Period, Roche shall advise ArQule in writing of its decision to (i) effect the Exercise Option pursuant to Section 4.3 below, (ii) extend the Option Term by a period of up to an additional * pursuant to Section 4.5, or (iii) terminate this Agreement pursuant to Section 17.4. Failure of Roche to timely advise ArQule in writing of its decision shall be deemed a termination pursuant to Section 17.4.
4.3 Payment Upon Option Exercise.
(a) If Roche effects the Option Exercise with respect to the Primary Compound and the Clinical Candidates, then Roche shall pay to ArQule concurrent with its notice that it is effecting the Option Exercise a one-time payment of * dollars ($*), which amount shall be non-refundable and non-creditable; and thereupon Roche shall obtain the License with respect to the associated Products. Roche shall also pay to ArQule the remaining amounts, if any, due under Section 4.1(b) concurrent with its notice that it is effecting the Option Exercise and any amounts due and payable pursuant to Section 2.1(c)(3). If there are fewer than * Clinical Candidates as of the date of Option Exercise, Roche may elect, in a writing delivered to ArQule at the time of the Option Exercise, for its License to extend to additional Back-Up Compounds, up to the number of compounds fewer than * as to which Roche would otherwise have a License. For example, if there are * Clinical Candidates as of the date of Option Exercise, then Roche shall have the right to extend the License to * additional Back-Up Compound. If Roche desires to exercise such election, then Roche shall give such written notice to ArQule of its election, and Roche's rights to other Back-Up Compounds that * during the * month period after the Option Term shall become null and void.
(b) If Roche effects the Option Exercise with respect to the Primary Compound, the Clinical Candidates and the Potential Optioned Compounds, then Roche shall pay to ArQule concurrent with its notice
- 14 - {PAGE}
that it is effecting the Option Exercise a one-time payment of * dollars ($*), which amount shall be non-refundable and non-creditable; and thereupon Roche shall obtain the License with respect to the associated Products. Roche shall also pay to ArQule the remaining amounts, if any, due under Section 4.1(b) concurrent with its notice that it is effecting the Option Exercise and any amounts due and payable pursuant to Section 2.1(c)(3).
4.4 License Rights Maintenance Fees.
(a) Major Indications. Roche shall pay to ArQule, in order to maintain the License (in the event that the Option Exercise has occurred) and the other provisions of this Agreement with respect to such Product, the following nonrefundable payments (shown in millions of US dollars) upon the first occurrence of the following events for each Product that is for a Major Indication:
{TABLE} {CAPTION} First Second Third Major Major Major Event Indication Indication Indication ----- ---------- ---------- ---------- {S} {C} {C} {C} * * * * {/TABLE}
(b) Other Indications. Roche shall pay to ArQule, in order to maintain the License (in the event that the Option Exercise has occurred) and the other provisions of this Agreement with respect to such Product, the following nonrefundable payments (shown in millions of US dollars) upon the first occurrence of the following events for each Product that is for an Other Indication:
{TABLE} {CAPTION} Any Other Event Indication ----- ---------- {S} {C} * * {/TABLE}
(c) Clinical Candidates. Roche shall pay to ArQule, in order to maintain the option set forth in Section 2.1(a), or the License (in the event that the Option Exercise has occurred) and the other provisions of this Agreement with respect to such Product, the following non-refundable and non-creditable payments for each Clinical Candidate developed in the Field:
(i) * dollars ($*) upon the first *; and
(ii) * dollars ($*) upon the first *. In the event that ArQule progresses a Clinical Candidate to * or * without *, such payment shall be due upon the first such Filing, in addition to any other payments triggered by such Filing.
- 15 - {PAGE}
(d) Timing of Payments. Each payment in Section 4.4 (a) through 4.4 (c) shall be due and payable by Roche within * after occurrence of the applicable event.
(e) Successive Events. Roche shall make each of such payments only once for the first occurrence of the requisite event for such Product or Clinical Candidate, regardless of how many times the event may be subsequently achieved with such Product or Clinical Candidate.
(f) Effect on Royalty Payments. No amount payable under this Article 4 shall reduce any royalties payable under Article 5 except that the payments set forth in Sections 4.4 (a) and 4.4(b) corresponding to US Launch and EU Launch events shall result in a credit of *% of each such payment (if any) against Roche's royalty obligations set forth in Article 5.
4.5 Payment for Extension of Option Term. If, at the end of the Option Term, the Option Trigger Date has not yet occurred, ArQule shall advise Roche in writing of the aspects of the deliverables not achieved and a proposed budget to complete such deliverables by *. If Roche has a positive interest to continue the Strategic Alliance but not yet to exercise its Option, Roche may elect to extend the Option Term for one additional year, from *, to *, by giving written notice to ArQule and paying ArQule an amount equal to the amount of the proposed budget as described in the preceding sentence, but not to exceed * dollars ($*), on or before *. ArQule shall use the payment provided by Roche under this Section 4.5 only in support of the Strategic Alliance. In the event ArQule's actual expenditures for such additional year in support of the Strategic Alliance are less than the budgeted amount (or such lesser amount if the budgeted amount exceeds $*), ArQule shall return to Roche such difference no later than *. However, Roche shall not have any responsibility or liability to ArQule for any actual expenditures exceeding the budgeted amount.
ARTICLE 5 ROYALTIES
5.1 Royalties. Roche shall pay to ArQule the following payments based on the Net Sales of a given Product, which payments shall be subject to adjustment as provided in this Article 5. Such royalty payments shall be calculated by multiplying the percentages specified below by the * Net Sales of such Product and as provided further in Section 7.2:
{TABLE} {CAPTION} ANNUAL NET SALES PERCENT (%) OF NET SALES ---------------- ------------------------ (IN MILLIONS OF US DOLLARS) {S} {C} * * {/TABLE}
5.2 Term of Royalty Payments. Roche's obligation to make royalty payments to ArQule under Section 5.1 with respect to a Product shall commence on the Launch of such Product in any country. The Adjusted Gross Sales in a given
- 16 - {PAGE}
country shall be included for purposes of calculating royalties under Section 5.1 from such Launch date until the later of (a) expiration of the last to expire Valid Claim Covering the sale of such Product in such country and (b) * from the Launch of such Product in such country. For purposes of this Section 5.2, the EU will be considered as one country.
5.3 Adjustments Related to Valid Claims from ArQule Patent Rights. With respect to a given Product in a given calendar quarter, if in a country of the Territory no Valid Claim from ArQule Patent Rights Covers the sale of such Product, then Roche may calculate royalties for such Product using only * percent (*%) of the amount of Adjusted Gross Sales that Roche would have used for such country to calculate royalties for such Product if a Valid Claim from ArQule Patent Rights Covered such Product in such country; provided however that if a Valid Claim from ArQule Patent Rights Covering such Product later exists in such country, Roche shall resume calculating and paying royalties using one hundred percent (100%) of such amount.
5.4 Adjustments Related to Valid Claims from Joint Patent Rights. With respect to a given Product in a given calendar quarter, if in a country in the Territory (a) no Valid Claim from an ArQule Patent Right Covers such Product, but (b) only a Valid Claim or Claims from one or more Joint Patent Rights Covers such Product, and (c) Roche sublicenses the Product to a Third Party and, but for the provisions of this Agreement, by operation of the law of such country, ArQule must consent to such sublicense, then Roche may calculate royalties for such Product with respect to such calendar quarter by including only * percent (*%) of the amount of Adjusted Gross Sales that Roche would have otherwise included for such country to calculate royalties for such Product if a Valid Claim from ArQule Patent Rights Covered it as well; provided, however, that if such Product subsequently is Covered in such country by ArQule Patent Rights as well, Roche shall resume calculating and paying royalties using one hundred percent (100%) of such amount. In the event that (x) no Joint Patent Rights Cover such Product, or (y) for a sublicense described in clause (c) of the preceding sentence, no consent would, but for the provisions of this Agreement, be required in a country, then Roche may calculate royalties for such Product using only * percent (*%) of the amount of Adjusted Gross Sales that Roche would have used for such country to calculate royalties for such Product if a Valid Claim from ArQule Patent Rights Covered such Product in such country; provided however that if, subsequent to such time, neither condition described in clause (x) or clause (y) of this sentence any longer exists, Roche shall resume calculating and paying royalties using * percent (*%) of such amount during the time they are satisfied.
5.5 Adjustments Related to Third Party Competition. With respect to a given Product in a given calendar quarter, if in a country of the Territory (a) a Third Party is selling a Bioequivalent Product, (b) Roche has an obligation to make payments under this Agreement with respect to Adjusted Gross Sales of the given Product in such country, (c) a Valid Claim Covers the sale of the Bioequivalent Product in such country, (d) in such country, sales of units of Bioequivalent Products
- 17 - {PAGE}
(adjusted as necessary so that units of Bioequivalent Products and Products are comparable) in aggregate total at least * percent (*%) of the aggregate sales of units of Bioequivalent Products and Products as measured at the end of such calendar quarter, and (e) Roche has, if it is reasonable under the circumstances, brought in such country and continued to diligently prosecute a patent infringement suit under any relevant Valid Claims against the Third Party or another in privity with respect to such Bioequivalent Product, then Roche shall have the right to calculate royalties with respect to such calendar quarter by including only * percent (*%) of the amount of Adjusted Gross Sales that Roche would have otherwise included for such country to calculate sales-based payments if no Bioequivalent Product existed in such country.
5.6 Third Party Payments. ArQule shall be solely responsible for all payments to Third Parties incurred pursuant to any license agreements entered into by ArQule prior to and as of the Effective Date. Roche shall be solely responsible for all payments to Third Parties incurred pursuant to license agreements entered into by Roche prior to, as of or after the Effective Date. With respect to license agreements related to any Product and entered into by ArQule after the Effective Date but prior to the date of the Option Exercise, the Parties shall equally share the responsibility for all payments due to Third Parties made pursuant to such license agreements; provided, however, that if Roche does not agree in writing to the terms and conditions of such license agreement, then ArQule shall be solely responsible, and further provided that subsequent to the date of the Option Exercise, Roche shall be solely responsible for all such payments.
If a Third Party claims a payment is due from ArQule under a license agreement related to any Product and entered into by ArQule and ArQule does not agree to make such payment, during the Agreement Term ArQule shall immediately advise Roche in writing of such disagreement and shall use Reasonable Diligence to provide Roche with a right to assume such agreement.
5.7 Combination Products. In the event Roche or any of its Affiliates or sublicensees intends to sell a Combination Product, the Parties shall meet approximately one (1) year prior to the anticipated commercial launch of such Combination Product to negotiate in good faith and agree to an appropriate adjustment to the calculation of Adjusted Gross Sales to reflect the relative significance and value (including consideration of relative market share, sales potential and price potential) of the Product and the other pharmaceutically active agent(s) contained in the Combination Product. If, after good faith negotiations (not to exceed ninety (90) days), the Parties cannot agree to an appropriate adjustment, Adjusted Gross Sales shall equal Adjusted Gross Sales of the Combination Product multiplied by a fraction, the numerator of which is the reasonable fair market value (including consideration of relative market share, sales potential and price potential) of the Product and the denominator of which is the reasonable fair market value (including consideration of relative market share, sales potential and price potential) in the aggregate of all pharmaceutically active agents contained in the Combination Product. If the Parties cannot agree to the relevant fair market
- 18 - {PAGE}
values for purposes of the preceding sentence, such disagreement shall be resolved in accordance with the dispute resolution procedure specified in Section 18.3.
5.8 Application of Adjustments. For each Product with respect to which Roche is entitled to an adjustment in royalty payments pursuant to Sections 5.3, 5.4 and 5.5, such adjustment shall be applied pursuant to only the first to occur of the events described or referred to in each of the foregoing sections, and not to any subsequent event. Notwithstanding the foregoing, or any other provision of this Agreement, in no event shall any credit or adjustment pursuant to Sections 5.3, 5.4 or 5.5 result in ArQule receiving royalties for a given calendar quarter pursuant to Section 5.1 in an amount less than * percent (*%) of the amounts set forth therein if no adjustment(s) had been made. Credits and adjustments not utilized pursuant to the immediately preceding sentence may be carried forward to any quarter that the credit or adjustment is not fully utilized in accordance with this Section 5.8 until utilized.
5.9 Allowances to Third Parties. In case of a sale or disposal of a Product for value other than in an arm's length transaction exclusively for money, such as barter or counter-trade, sales shall be calculated using the fair market value of such Product (if higher than the stated sales price) in the country of disposal.
ARTICLE 6 MILESTONE PAYMENTS
6.1 Milestone Adjusted Gross Sales Payments. Roche shall pay to ArQule the following one-time payments for each Product, payable the first time the applicable sales threshold is met, based upon the total Adjusted Gross Sales throughout the world for such Product.
{TABLE} {CAPTION} ANNUAL ADJUSTED GROSS SALES GREATER THAN PAYMENT (IN MILLIONS OF US DOLLARS) ---------------------------------------- ----------------------------------- (IN MILLIONS OF US DOLLARS) {S} {C} * * {/TABLE}
ARTICLE 7 PAYMENT, REPORTING, AUDITING
7.1 Currency and Conversion.
(a) All payments under this Agreement are stated and shall be payable in US Dollars by wire transfer of immediately available funds in accordance with the instructions of the Party being paid.
(b) Whenever calculation of Adjusted Gross Sales requires conversion from any foreign currency, Roche shall convert the amount of Adjusted Gross Sales in such foreign currency as computed in Roche's central Swiss
- 19 - {PAGE}
Francs Sales Statistics for the countries concerned, using for internal foreign currency translation Roche's then current standard practices actually used on a consistent basis in preparing its audited financial statements.
(c) For sublicensees in a country, when calculating the Adjusted Gross Sales, Roche shall require the sublicensee to report to Roche the amount of such sales within * from the end of the reporting period, after having converted each applicable monthly sales in foreign currency into Swiss Francs using the average rate of exchange published in the Wall Street Journal (or some other source agreed upon by the Parties for any particular country) for each month of the reporting period.
7.2 Payments.
(a) After the Launch of a Product in any country of the Territory:
(i) Roche shall calculate royalty payments set forth in Article 5 and milestone payments set forth in Article 6 quarterly as of * (each being the last day of
282568
|
ArQule
As referenced in this Strategic Alliance Agreement:
ARQULE, INC – Jersey corporation, having its principal place of business at 340 Kingsland
Street, Nutley, New Jersey 07110 (collectively "Roche") and, on the other hand,
ARQULE, INC ., a Delaware corporation, having its principal place of business at
19 Presidential Way, Woburn, Massachusetts 01801-5140 ("ArQule").
INTRODUCTION
1. ArQule has _____________
ArQule, Inc – Nutley, New Jersey 07110
Attn: Chief Patent Counsel
All notices required or permitted under this Article 14 to ArQule shall
be given to:
ArQule, Inc .
19 Presidential Way
Woburn, Massachusetts 01801-5140
Attn: General Counsel
-37-
{PAGE}
with copies of all notices to:
Arnold & Porter
555 Twelfth _____________
ArQule, Inc – 14, or such
other address as the addressee shall have specified in a written notice
actually received by the addresser.
If to ArQule:
ArQule, Inc .
19 Presidential Way
Woburn, Massachusetts 01801-5140
Attn: General Counsel
and
Arnold & Porter
1600 Tysons Boulevard, Suite 900
McLean, Virginia 22102
Attn: _____________
ARQULE, INC – Agreement to be
executed in their names by their properly and duly authorized officers or
representatives as of the date first written above.
ARQULE, INC . HOFFMANN-LA ROCHE INC.
By: _____________________________ By: _________________________________
Title: ____________________________ Title: ______________________________
F. HOFFMANN-LA ROCHE LTD
By: _________________________________
Title: _____________________________
By: _____________
dt 204359
;
Genentech
As referenced in this Strategic Alliance Agreement:
Genentech, Inc – ownership of which is directly or indirectly
common to the majority ownership of a Party. Anything to the contrary
in this paragraph notwithstanding, Genentech, Inc ., a Delaware
corporation, and Chugai Pharmaceutical Co., Ltd., a Japanese
corporation, (each, a "Roche Entity"), shall not be deemed an Affiliate
of _____________
dt 204270
;
Arnold & Porter
As referenced in this Strategic Alliance Agreement:
Arnold & Porter – be given to:
ArQule, Inc.
19 Presidential Way
Woburn, Massachusetts 01801-5140
Attn: General Counsel
-37-
{PAGE}
with copies of all notices to:
Arnold & Porter
555 Twelfth Street, NW
Washington, D.C. 20004
Attn: David Marsh, Esq.
Notices under this Section shall be effective when delivered to _____________
Arnold & Porter – written notice
actually received by the addresser.
If to ArQule:
ArQule, Inc.
19 Presidential Way
Woburn, Massachusetts 01801-5140
Attn: General Counsel
and
Arnold & Porter
1600 Tysons Boulevard, Suite 900
McLean, Virginia 22102
Attn: Steve Parker, Esq.
If to Roche:
F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
_____________
dt 205019
;
| F. Hoffmann-La Roche Ltd.;
Hoffmann-La Roche Inc.
|
Preview
Full Doc
 | 2001 |
Alliance Agreement
Alliance Agreement (261K)
Doc #301259: Click preview link for longer preview.
ALLIANCE AGREEMENT
between
BLUE CROSS AND BLUE SHIELD OF KANSAS, INC.
and
ANTHEM INSURANCE COMPANIES, INC.
Dated as of May 30, 2001
-------------------------------------------------------------------------------- {PAGE}
Table of Contents -----------------
{TABLE} {CAPTION} Page ---- {S} {C} ARTICLE I DEFINITIONS.......................................................................... 1 SECTION 1.01. Certain Defined Terms................................................................ 1
ARTICLE II TRANSACTION.......................................................................... 15 SECTION 2.01. The Conversion....................................................................... 15 SECTION 2.02. Sale and Purchase of the Shares...................................................... 17 SECTION 2.03. Purchase Price....................................................................... 17 SECTION 2.04. Closing.............................................................................. 17 SECTION 2.05. Closing Deliveries by BCBSKS......................................................... 18 SECTION 2.06. Closing Deliveries by Purchaser...................................................... 18 SECTION 2.07. Escrow Matters....................................................................... 18 SECTION 2.08. Additional Purchase Price............................................................ 23 SECTION 2.09. Special Distribution................................................................. 25
ARTICLE III REPRESENTATIONS AND WARRANTIES OF BCBSKS............................................. 25 SECTION 3.01. Organization and Authority........................................................... 25 SECTION 3.02. Ownership Interests.................................................................. 27 SECTION 3.03. Books and Records.................................................................... 28 SECTION 3.04. No Conflict.......................................................................... 28 SECTION 3.05. Consents and Approvals of Governmental Authorities................................... 28 SECTION 3.06. Financial Information; Books and Records............................................. 29 SECTION 3.07. No Undisclosed Liabilities........................................................... 30 SECTION 3.08. Receivables.......................................................................... 30 SECTION 3.09. Conduct in the Ordinary Course; Absence of Certain Changes, Events and Conditions.... 30 SECTION 3.10. Litigation........................................................................... 33 SECTION 3.11. Compliance with Laws................................................................. 34 SECTION 3.12. Environmental and Other Permits and Licenses; Related Matters........................ 34 SECTION 3.13. Material Contracts................................................................... 35 SECTION 3.14. Intellectual Property................................................................ 38 SECTION 3.15. Real Property........................................................................ 39 SECTION 3.16. Tangible Personal Property........................................................... 40 SECTION 3.17. Assets............................................................................... 41 SECTION 3.18. Significant Agreements............................................................... 41 SECTION 3.19. Suppliers............................................................................ 41 SECTION 3.20. Employee Benefit Matters............................................................. 42 SECTION 3.21. Labor Matters........................................................................ 44 SECTION 3.22. Key Employees........................................................................ 45 SECTION 3.23. Certain Interests.................................................................... 45 SECTION 3.24. Taxes................................................................................ 45 SECTION 3.25. Insurance............................................................................ 47 SECTION 3.26. Accounts; Lockboxes; Safe Deposit Boxes; Powers of Attorney.......................... 48 {/TABLE}
-i- {PAGE}
Table of Contents ----------------- (continued)
{TABLE} {CAPTION} Page ---- {S} {C} SECTION 3.27. Brokers........................................................................ 48 SECTION 3.28. No Pecuniary Interests......................................................... 49 SECTION 3.29. Computer Systems............................................................... 49 SECTION 3.30. Brokers and Agents............................................................. 49 SECTION 3.31. Government Contracts........................................................... 49 SECTION 3.32. Medicare Secondary Payor Rules................................................. 49 SECTION 3.33. Confidentiality of Personal Information........................................ 50 SECTION 3.34. Resolution of Charitable Claims, etc........................................... 50
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PURCHASER.................................... 50 SECTION 4.01. Organization and Authority of Purchaser........................................ 50 SECTION 4.02. No Conflict.................................................................... 51 SECTION 4.03. Brokers........................................................................ 52 SECTION 4.04. No Pecuniary Interest.......................................................... 52 SECTION 4.05. Consents and Approvals of Governmental Authorities............................. 52 SECTION 4.06. Investment Representations..................................................... 52 SECTION 4.07. Financial Ability to Perform................................................... 53 SECTION 4.08. No Litigation.................................................................. 53 SECTION 4.09. Charitable Claims, etc......................................................... 53
ARTICLE V ADDITIONAL AGREEMENTS.......................................................... 53 SECTION 5.01. Conduct of Business Prior to the Closing....................................... 53 SECTION 5.02. Access to Information.......................................................... 55 SECTION 5.03. Regulatory and Other Authorizations; Notices and Consents...................... 56 SECTION 5.04. Notice of Developments......................................................... 57 SECTION 5.05. No Solicitation or Negotiation................................................. 57 SECTION 5.06. Termination Fees............................................................... 58 SECTION 5.07. Directors...................................................................... 59 SECTION 5.08. Advisory Committees............................................................ 59 SECTION 5.09. Further Action................................................................. 59
ARTICLE VI EMPLOYEE MATTERS............................................................... 60 SECTION 6.01. Transferred Employees.......................................................... 60 SECTION 6.02. Maintenance of Certain Plans; Contributions.................................... 60 SECTION 6.03. Treatment of Transferred Employees............................................. 60 SECTION 6.04. Post-Closing Employment Levels................................................. 61 SECTION 6.05. Non-Competition/Non-Solicitation Agreements.................................... 62 SECTION 6.06. No Employment Agreement or Third Party Beneficiary Status...................... 62
ARTICLE VII TAX MATTERS.................................................................... 62 SECTION 7.01. Returns and Payments........................................................... 62 SECTION 7.02. Contests....................................................................... 63 SECTION 7.03. Conveyance Taxes............................................................... 63 {/TABLE}
-ii- {PAGE}
Table of Contents ----------------- (continued)
{TABLE} {CAPTION} Page ---- {S} {C} SECTION 7.04. Miscellaneous.................................................................. 63 SECTION 7.05. Tax Disputes................................................................... 63 SECTION 7.06. Special Distribution........................................................... 66
ARTICLE VIII CONDITIONS TO CLOSING.......................................................... 67 SECTION 8.01. Conditions to Each Party's Obligations......................................... 67 SECTION 8.02. Conditions to Obligations of BCBSKS............................................ 67 SECTION 8.03. Conditions to Obligations of Purchaser......................................... 68 SECTION 8.04. Frustration of Closing Conditions.............................................. 70
ARTICLE IX CERTAIN INDEMNIFICATION MATTERS................................................ 70 SECTION 9.01. Director and Officer Liability................................................. 70 SECTION 9.02. Procedure...................................................................... 70 SECTION 9.03. Maintenance of D&O Liability Policies.......................................... 71
ARTICLE X TERMINATION AND WAIVER......................................................... 71 SECTION 10.01. Termination.................................................................... 71 SECTION 10.02. Effect of Termination.......................................................... 73 SECTION 10.03. Waiver......................................................................... 74
ARTICLE XI GENERAL PROVISIONS............................................................. 74 SECTION 11.01. Expenses....................................................................... 74 SECTION 11.02. Notices........................................................................ 75 SECTION 11.03. Public Announcements........................................................... 75 SECTION 11.04. Headings....................................................................... 76 SECTION 11.05. Severability................................................................... 76 SECTION 11.06. Entire Agreement............................................................... 76 SECTION 11.07. Assignment..................................................................... 76 SECTION 11.08. No Third Party Beneficiaries................................................... 76 SECTION 11.09. Amendment...................................................................... 77 SECTION 11.10. Governing Law; Consent to Jurisdiction......................................... 77 SECTION 11.11. Counterparts................................................................... 77 SECTION 11.12. Specific Performance........................................................... 77 SECTION 11.13. Survival of Representations, Warranties and Agreements......................... 77 {/TABLE}
EXHIBITS
2.01(a) Plan of Conversion (Form) 8.01(c) Governmental Consents and Approvals 8.02(d) Opinion of Purchaser's Counsel (Form) 8.03(d) Opinion of BCBSKS's Counsel (Form) 8.03(e) Third Party Consents
-iii- {PAGE}
ALLIANCE AGREEMENT ------------------
ALLIANCE AGREEMENT, dated as of May 30, 2001, by and between BLUE CROSS AND BLUE SHIELD OF KANSAS, INC., a Kansas mutual life insurance company ("BCBSKS"), ------ and ANTHEM INSURANCE COMPANIES, INC., an Indiana mutual insurance company ("Anthem" or "Purchaser"). ------ ---------
W I T N E S S E T H: - - - - - - - - - -
WHEREAS, the Board of Directors of BCBSKS is currently preparing a plan of conversion (such plan of conversion as adopted, and as may be amended from time to time in accordance herewith, the "Plan of Conversion") pursuant to which ------------------ BCBSKS will be converted (the "Conversion") from a mutual insurance company to a ---------- stock insurance corporation pursuant to the Kansas Insurance Code; and
WHEREAS, the Plan of Conversion will provide for and be contingent on the sale (the "Sale") of all of the shares of common stock of BCBSKS (the "Common ---- ------ Stock") immediately following the Conversion to Purchaser upon the terms and ----- subject to the conditions set forth in this Agreement;
NOW, THEREFORE, in consideration of the premises and the mutual agreements and covenants hereinafter set forth, Purchaser and BCBSKS hereby agree as follows:
ARTICLE I
DEFINITIONS
SECTION 1.01. Certain Defined Terms. As used in this Agreement, the --------------------- following terms shall have the following meanings:
"Action" means any written claim, formal action, suit, arbitration or ------ proceeding by or before any Governmental Authority.
"Additional Purchase Price" has the meaning specified in Section 2.03. -------------------------
"Affiliate" means, with respect to any specified Person, any other Person --------- that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such specified Person.
"Agreement" or "this Agreement" means this Alliance Agreement, dated as of --------- -------------- May 30, 2001, between BCBSKS and Purchaser (including the Exhibits hereto, the {PAGE}
Disclosure Statement, and the Purchaser Disclosure Statement) and all amendments hereto made in accordance with the provisions of Section 11.09.
"Anthem Holding Company" means the public holding company to be formed in ---------------------- connection with a demutualization of Anthem to hold all of the shares of its common stock, and which shall, as of the Closing Date, hold all of such shares (provided that for purposes of this Agreement if Anthem shall not have demutualized prior to the Closing Date references to Anthem Holding Company herein shall be deemed not to have any effect).
"Anthem West" means Anthem West Company, Inc., an Indiana corporation and a ----------- wholly-owned direct subsidiary of Anthem.
"Assets" means the properties and assets (real, personal or mixed, tangible ------ or intangible) used or held for use in connection with , necessary for the conduct of, or material to, the Business.
"BCBS" means BCBSKS and its Affiliates, collectively. ----
"BCBSA" means the Blue Cross Blue Shield Association. -----
"BCBSKS" has the meaning specified in the recitals to this Agreement, ------ except as provided in Section 7.04(a).
"BCBSKS's knowledge" or "knowledge of BCBSKS" means to the actual knowledge ------------------ ------------------- of the Named Officers, after reasonable investigation but without giving effect to imputed knowledge.
"Burdensome Condition" means, with respect to any required regulatory -------------------- approval, and/or any Law, rule, regulation or administrative interpretation made, adopted, declared, or announced (written or orally) by any Governmental Authority of the State of Kansas after the date hereof but on or prior to the Closing Date to be applicable to Purchaser (or BCBSKS or any of the Affiliates of BCBSKS acquired by Purchaser pursuant to this Agreement), (i) any term, condition, restriction or limitation that would be reasonably likely to have a Material Adverse Effect on BCBS; or (ii) any statutory or regulatory obligation on BCBS that materially differs from those statutory or regulatory obligations
301259
|
Goldman, Sachs
As referenced in this Alliance Agreement:
Goldman, Sachs & Co. – or Anthem
Holding Company to consummate the transactions contemplated by this Agreement or
by the Escrow Agreement.
SECTION 4.03. Brokers. Except for Goldman, Sachs & Co. , no broker,
-------
finder or investment banker is entitled to any brokerage, finder's or other fee
or commission in connection with the _____________
dt 274504
;
Debevoise
As referenced in this Alliance Agreement:
Debevoise & Plimpton – consummation of the transaction contemplated by this Agreement
shall take place at a closing (the "Closing") to be held at the offices of
-------
Debevoise & Plimpton at 10:00 A.M. on the earliest practicable date after the
conditions to the obligations of the parties set forth in Article _____________
Debevoise & Plimpton
– Kansas, Inc.
1133 Topeka Boulevard
Topeka, KS 66629
Attention: William H. Pitsenberger, General Counsel
Telecopy No.: (785) 291-7329
with a copy to:
Debevoise & Plimpton
875 Third Avenue
New York, New York
Attention: James C. Scoville
Telecopy No.: (212) 909-6836
(b) if to Purchaser to:
Anthem _____________
dt 272839
;
| Blue Cross and Blue Shield of Kansas, Inc.;
Anthem Insurance Companies, Inc.
|
Preview
Full Doc
 | 2002 |
Strategic Alliance Agreement [Amended and Restated 2002]
Strategic Alliance Agreement [Amended and Restated 2002] (218K)
Doc #301990: Click preview link for longer preview.
AMENDED AND RESTATED
STRATEGIC ALLIANCE AGREEMENT
BY AND BETWEEN
PENWEST PHARMACEUTICALS CO.
AND
ENDO PHARMACEUTICALS INC.
DATED AS OF APRIL 2, 2002
------------------------------
THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST IN ACCORDANCE WITH RULE 24b-2 OF THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN ***. {PAGE} TABLE OF CONTENTS
{TABLE} {S} {C} 1. Definitions............................................................. 1 2. [INTENTIONALLY OMITTED.]................................................ 2 3. Certification Period(s)................................................. 2 3.1 Covenants.......................................................... 2 3.2 Communication & Access............................................. 2 3.3 Reports............................................................ 2 3.4 Supply............................................................. 2 3.5 U.S. Certification Budget; Election Not to Continue Participation.. 2 3.6 Rest of the World.................................................. 4 3.7 Certification Reconciliations...................................... 4 4. Marketing Period........................................................ 5 4.1 Endo Covenants..................................................... 5 4.2 Penwest Covenants.................................................. 5 4.3 Rest of the World.................................................. 6 4.4 TIMERx Supply; Invoices During the Marketing Period................ 6 4.5 Royalties; Recoupment of Certification Excess...................... 7 4.6 Reduction in Royalties............................................. 7 4.7 Timing of Royalty Payments......................................... 8 4.8 Records; Audits.................................................... 9 4.9 Rate of Exchange for Non-U.S. Royalties............................ 9 5. Term and Termination.................................................... 9 5.1 Term............................................................... 10 5.2 Receipt of Non-Approvable Letter................................... 10 5.3 Mutual Agreement................................................... 10 5.4 Unfavorable or Inconclusive Results................................ 10 5.5 Termination of Participation in a Certification Period............. 10 5.6 Termination of an Exclusivity Period for Failure to Meet Minimum Net Realization Levels..................................... 11 5.7 Failure to Launch or Discontinuation of Active Marketing........... 11 5.8 Material Breaches.................................................. 11 5.9 Endo's Bankruptcy; Insolvency...................................... 12 5.10 Penwest's Bankruptcy; Insolvency................................... 12 5.11 Survival........................................................... 12 6. Ownership and Licenses.................................................. 12 6.1 Retention of Ownership; Inventorship; Assignment.................. 12 6.2 Filing and Prosecution of Patents.................................. 13 6.3 Licenses Granted................................................... 13 6.4 Exclusivity........................................................ 14 6.5 Licenses as to Product Technology.................................. 15 6.6 Endo's License to TIMERx........................................... 15 6.7 Endo's Continuing License.......................................... 15 {/TABLE}
i {PAGE} {TABLE} {S} {C} 6.8 Penwest's Continuing License....................................... 17 6.9 License to Improvement Technology.................................. 19 6.10 License to Endo Test and Regulatory Data........................... 20 6.11 License to Penwest Test and Regulatory Data........................ 20 6.12 Marking of the Product............................................. 21 7. Supply of TIMERx; Oxymorphone........................................... 21 7.1 Sales of TIMERx.................................................... 21 7.2 Quality Control Testing............................................ 21 7.3 Non-Conforming Shipments........................................... 21 7.4 Failure to Supply TIMERx........................................... 22 7.5 Failure to Supply Oxymorphone ADS or Finished Product.............. 23 7.6 Access............................................................. 24 7.7 TIMERx Ordering Process............................................ 25 7.8 Estimates of TIMERx................................................ 25 7.9 Actual TIMERx Supply............................................... 25 7.10 Notifications; Governmental Inspections............................ 25 7.11 Manufacturing Agreements........................................... 26 8. Use of Trademarks....................................................... 27 8.1 Benefit of Trademarks.............................................. 27 8.2 Protection of Trademarks........................................... 27 8.3 Acknowledgement of Ownership of Trademarks......................... 27 8.4 Prior Approval of Use of Trademarks................................ 28 9. Representations, Warranties and Indemnities............................. 28 9.1 Mutual Authorization Representations............................... 28 9.2 Penwest Representations............................................ 28 9.3 Mutual Licenses, Permits and Authorizations Representations........ 29 9.4 Disclaimer......................................................... 29 9.5 Penwest's Indemnification of Endo.................................. 29 9.6 Endo's Indemnification of Penwest.................................. 30 9.7 Limitation on Indemnification...................................... 30 9.8 Procedure.......................................................... 31 9.9 No Liability....................................................... 31 10. Confidentiality and Non-Solicitation.................................... 32 10.1 Confidentiality; Exceptions........................................ 32 10.2 Public Announcements............................................... 33 10.3 Non-Solicitation................................................... 33 11. Infringement............................................................ 33 11.1 Notice of Infringement............................................. 33 11.2 Non-Covered Infringement........................................... 34 11.3 Penwest's Institution of Suit...................................... 34 11.4 Joint Suits........................................................ 34 11.5 Endo's Institution of Suit......................................... 34 11.6 Abandonment of Suit................................................ 34 11.7 Patent Enforcement Litigation...................................... 35 {/TABLE}
ii {PAGE} {TABLE} {S} {C} 12. Escalation Procedures................................................... 35 13. Arbitration............................................................. 36 14. Miscellaneous........................................................... 37
Exhibits Definitions Exhibit......................................................... 40 Exhibit 1.17 - Trademarks................................................... 52 Exhibit 1.28 - Accounting and Attribution Standards and Principals.......... 53 Exhibit 1.32 - Penwest Patents.............................................. 56 Exhibit 6.1 - Certain Jointly Filed Provisional Patent Applications......... 58 {/TABLE}
iii {PAGE} AMENDED AND RESTATED
STRATEGIC ALLIANCE AGREEMENT
THIS AGREEMENT is entered into as of the 2nd day of April, 2002 (the "Restatement Date"), by and between Penwest Pharmaceuticals Co. ("Penwest"), a Washington corporation with its principal place of business at 2981 Route 22, Patterson, New York 12563, and Endo Pharmaceuticals Inc., a Delaware corporation with its principal place of business at 100 Painters Drive, Chadds Ford, Pennsylvania 19317 ("Endo").
WHEREAS, Penwest and Endo are party to that certain Strategic Alliance Agreement, dated as of September 17, 1997 (the "Old Agreement");
WHEREAS, in light of changes that have occurred at both Penwest and Endo since the execution of the Old Agreement, Penwest and Endo now wish to amend and restate the Old Agreement in its entirety;
WHEREAS, Penwest has developed an extended-release agent covered by one or more patents, patent applications, know-how and other proprietary technology, which agent Penwest markets under the name and mark "TIMERx(R)" ("TIMERx");
WHEREAS, Endo manufactures and markets the product marketed under the name "Numorphan(R)", having as an active drug substance oxymorphone HCl ("Oxymorphone") and has developed know-how and other proprietary technology with respect thereto;
WHEREAS, the parties, pursuant to the Old Agreement, have co-developed a product combining Oxymorphone and TIMERx, which product is a solid-dosage extended-release pharmaceutical for oral administration in humans in one or more dosage strengths and which product is referred to by the parties as "EN 3202";
WHEREAS, the parties desire to provide for the further development and commercialization of EN 3202 as provided herein; and
WHEREAS, Endo desires to contract for a supply of TIMERx for use in the manufacture of EN 3202, and Penwest is willing to supply the same provided that Endo agrees to obtain all of its and its Affiliates' and sublicensees' requirements of TIMERx from Penwest as provided herein;
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
1. Definitions. Certain terms used herein are defined in Sections 1.1 through 1.44 of the Definitions Exhibit attached hereto and incorporated herein by this reference.
1 {PAGE} 2. [INTENTIONALLY OMITTED.]
3. Certification Period(s).
3.1 Covenants. Each of Penwest and Endo will exert its Best Commercial Efforts: (i) to perform the respective Certification Tasks allotted to it; (ii) to do so in accordance with the applicable Certification Budget; and (iii) to assist and to cooperate as requested with the other party's Best Commercial Efforts to do the same as to its own Certification Tasks.
3.2 Communication & Access. Each party will, promptly and throughout the term of this Agreement, provide to the other party all necessary or useful information in or coming into its possession or reasonably available to it to support the achievement of the Certification Tasks. Notwithstanding anything else to the contrary contained herein, nothing shall require either party to disclose confidential information for which such party has an obligation of confidentiality to a third party, but each party will exert its Best Commercial Efforts to bring to the attention of the Alliance Committee any such third party restrictions as may be relevant to its role hereunder.
3.3 Reports. Each Project Contact will be available throughout each Certification Period to answer any reasonable questions from the other party's Project Contact, as appropriate.
3.4 Supply. During each Certification Period in which it is participating, Endo shall provide Oxymorphone and related materials reasonably required to support the applicable Certification Tasks, and Penwest shall provide all Formulated TIMERx reasonably required therefor, all as shall be more fully described in the applicable Certification Tasks adopted by Committee Action. The costs of such materials will be treated as among the parties' respective expenditures pursuant to the applicable Certification Budget, using for this purpose the Formulated TIMERx Price as to the TIMERx and the Oxymorphone Price as to the Oxymorphone. Where, as permitted hereunder, a party is not participating in a Certification Period, it will sell such materials to the participating party pursuant to Section 6.8.4 hereof or Article 7 hereof, as applicable, and the price paid therefor shall be treated as part of the buyer's expenditures pursuant to the applicable Certification Budget.
3.5 U.S. Certification Budget; Election Not to Continue Participation. The parties hereby agree that the Alliance Committee, by Committee Action, shall on an annual basis approve the U.S. Certification Budget for the next twelve-month period. The parties hereby further agree that each party will share equally the total costs of each entire Certification Budget for the U.S. Certification Period regardless of which party is allocated one or more of the relevant Certification Tasks, subject to Section 5.5 hereof. If at any time, one party but not the other
2 {PAGE} desires to spend sums or devote resources not covered by a particular U.S. Certification Budget to complete Certification Tasks, then, upon such party giving notice to the other party under Section 5.5 hereof, the following shall apply (in addition to the provisions of Section 5.5 hereof):
3.5.1 The party that does not participate further in such U.S. Certification Period shall not be required to contribute to the reconciliations for the costs of such Certification Period under Section 3.7 hereof. Rather, a Certification Excess shall be established with respect to the Product in the U.S., which shall equal the sums such party would have paid under Section 3.7 hereof for such costs, had it fully participated in such Certification Period, but did not pay due to its election under this Section.
3.5.2 If Endo is the party electing not to participate further in such U.S. Certification Period, then Section 6.8 hereof shall apply and the other provisions of this Agreement shall remain in effect in accordance with their terms and the terms of Section 6.8; provided, however, that, if a Certification Excess exists pursuant to Section 3.5.1 hereof (where Endo is the non-participating party), Penwest shall pay Endo proportionately less than the Applicable Percentage of the relevant Net Realization from the Product in the U.S., until Penwest has thereby recouped the amount of such Certification Excess. (That is, for example, if the total resources devoted by both Endo and Penwest to such Certification Period is *** in this example, and Penwest bore *** and Endo bore *** of that total prior to Endo's making its election not to participate further, and if the Applicable Percentage is 50%, then Penwest would pay Endo *** of the Net Realization from the Product in the U.S. until Penwest had thereby recouped the *** total Certification Excess, which would occur in this example when the total of such Net Realization reaches ***.)
3.5.3 If Penwest is the party electing not to participate further in such U.S. Certification Period, then Section 6.7 shall apply and the other provisions of this Agreement shall remain in effect in accordance with their terms and the terms of Section 6.7; provided, however, that, if a Certification Excess exists pursuant to Section 3.5.1 hereof (where Penwest is the non-participating party), Endo shall pay Penwest proportionately less than the Applicable Percentage of the relevant Net Realization from the Product in the U.S., until Endo has thereby recouped the amount of such Certification Excess. (That is, for example, if the total resources devoted by both Endo and Penwest to such Certification Period is *** in this example, and Endo bore *** and Penwest bore *** of that total prior to Penwest's making its
3 {PAGE} election not to participate further, and if the Applicable Percentage is 50%, then Endo would pay
301990
|
Penwest Pharma
As referenced in this Strategic Alliance Agreement [Amended and Restated 2002]:
PENWEST PHARMACEUTICALS CO – y60437ex10-18.txt
{DESCRIPTION}A/R STRATEGIC ALLIANCE AGREEMENT
{TEXT}
{PAGE}
Exhibit 10.18
AMENDED AND RESTATED
STRATEGIC ALLIANCE AGREEMENT
BY AND BETWEEN
PENWEST PHARMACEUTICALS CO .
AND
ENDO PHARMACEUTICALS INC.
DATED AS OF APRIL 2, 2002
------------------------------
THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN FILED SEPARATELY
WITH THE _____________
Penwest Pharmaceuticals Co – RESTATED
STRATEGIC ALLIANCE AGREEMENT
THIS AGREEMENT is entered into as of the 2nd day of April, 2002 (the
"Restatement Date"), by and between Penwest Pharmaceuticals Co . ("Penwest"), a
Washington corporation with its principal place of business at 2981 Route 22,
Patterson, New York 12563, and Endo Pharmaceuticals Inc., _____________
PENWEST PHARMACEUTICALS CO – hereto have caused their duly
authorized officers to execute and acknowledge this Agreement as of the date
first written above.
ENDO PHARMACEUTICALS INC. PENWEST PHARMACEUTICALS CO .
By: /s/ CAROL A. AMMON By: /s/ TOD R. HAMACHEK
--------------------------------- --------------------------------------
Its: Chairman & CEO Its: Chairman & CEO
--------------------------------- --------------------------------------
Address: Address:
100 Painters Drive 2981 _____________
Penwest Pharmaceuticals Co – promotion of the Product hereunder, pursuant to Section 8
hereof.
1.18 "Escalation Officer" shall mean the Chairman and Chief
Executive Officer of Penwest Pharmaceuticals Co . (currently
Tod Hamachek), and the Chief Executive Officer of Endo
(currently Carol Ammon), and the persons holding such
positions from time to _____________
dt 274545
;
|
Hale and Dorr
As referenced in this Strategic Alliance Agreement [Amended and Restated 2002]:
Hale and Dorr – 558-9682 FAX: (845) 878-3498
Attn: Carol A. Ammon Attn: Tod R. Hamachek
cc: Steven D. Singer, Esq.
cc: Caroline B. Manogue Hale and Dorr LLP
FAX: (610) 558-9684 60 State Street
Boston, Massachusetts 02109
FAX: (617) 526-5000
39
{PAGE}
DEFINITIONS EXHIBIT
1. Definitions.
1. _____________
dt 273830
;
Endo Pharmaceuticals Inc.
|
Preview
Full Doc
 | 2002 |
Strategic Alliance Agreement [Amended and Restated]
Strategic Alliance Agreement [Amended and Restated] (218K)
Doc #321016: Click preview link for longer preview.
AMENDED AND RESTATED
STRATEGIC ALLIANCE AGREEMENT
BY AND BETWEEN
PENWEST PHARMACEUTICALS CO.
AND
ENDO PHARMACEUTICALS INC.
DATED AS OF APRIL 2, 2002
CONFIDENTIAL {PAGE}
TABLE OF CONTENTS
1. Definitions...............................................................1 2. [INTENTIONALLY OMITTED.]..................................................2 3. Certification Period(s)...................................................2 3.1 Covenants...........................................................2 3.2 Communication & Access..............................................2 3.3 Reports.............................................................2 3.4 Supply..............................................................2 3.5 U.S. Certification Budget; Election Not to Continue Participation...2 3.6 Rest of the World...................................................4 3.7 Certification Reconciliations.......................................4 4. Marketing Period..........................................................5 4.1 Endo Covenants......................................................5 4.2 Penwest Covenants...................................................5 4.3 Rest of the World...................................................6 4.4 TIMERx Supply; Invoices During the Marketing Period.................6 4.5 Royalties; Recoupment of Certification Excess.......................7 4.6 Reduction in Royalties..............................................7 4.7 Timing of Royalty Payments..........................................8 4.8 Records; Audits.....................................................9 4.9 Rate of Exchange for Non-U.S. Royalties.............................9 5. Term and Termination......................................................9 5.1 Term...............................................................10 5.2 Receipt of Non-Approvable Letter...................................10 5.3 Mutual Agreement...................................................10 5.4 Unfavorable or Inconclusive Results................................10 5.5 Termination of Participation in a Certification Period.............10 5.6 Termination of an Exclusivity Period for Failure to Meet Minimum Net Realization Levels.....................................11 5.7 Failure to Launch or Discontinuation of Active Marketing...........11 5.8 Material Breaches..................................................11 5.9 Endo's Bankruptcy; Insolvency......................................12 5.10 Penwest's Bankruptcy; Insolvency...................................12 5.11 Survival...........................................................12 6. Ownership and Licenses...................................................12 6.1 Retention of Ownership; Inventorship; Assignment..................12 6.2 Filing and Prosecution of Patents..................................13 6.3 Licenses Granted...................................................13 6.4 Exclusivity........................................................14 6.5 Licenses as to Product Technology..................................15 6.6 Endo's License to TIMERx...........................................15 6.7 Endo's Continuing License..........................................15
Confidential i {PAGE}
6.8 Penwest's Continuing License.......................................17 6.9 License to Improvement Technology..................................19 6.10 License to Endo Test and Regulatory Data...........................20 6.11 License to Penwest Test and Regulatory Data........................20 6.12 Marking of the Product.............................................21 7. Supply of TIMERx; Oxymorphone............................................21 7.1 Sales of TIMERx....................................................21 7.2 Quality Control Testing............................................21 7.3 Non-Conforming Shipments...........................................21 7.4 Failure to Supply TIMERx...........................................22 7.5 Failure to Supply Oxymorphone ADS or Finished Product..............23 7.6 Access.............................................................24 7.7 TIMERx Ordering Process............................................25 7.8 Estimates of TIMERx................................................25 7.9 Actual TIMERx Supply...............................................25 7.10 Notifications; Governmental Inspections............................25 7.11 Manufacturing Agreements...........................................26 8. Use of Trademarks........................................................27 8.1 Benefit of Trademarks..............................................27 8.2 Protection of Trademarks...........................................27 8.3 Acknowledgement of Ownership of Trademarks.........................27 8.4 Prior Approval of Use of Trademarks................................28 9. Representations, Warranties and Indemnities..............................28 9.1 Mutual Authorization Representations...............................28 9.2 Penwest Representations............................................28 9.3 Mutual Licenses, Permits and Authorizations Representations........29 9.4 Disclaimer.........................................................29 9.5 Penwest's Indemnification of Endo..................................29 9.6 Endo's Indemnification of Penwest..................................30 9.7 Limitation on Indemnification......................................30 9.8 Procedure..........................................................31 9.9 No Liability.......................................................31 10. Confidentiality and Non-Solicitation.....................................32 10.1 Confidentiality; Exceptions........................................32 10.2 Public Announcements...............................................33 10.3 Non-Solicitation...................................................33 11. Infringement.............................................................33 11.1 Notice of Infringement.............................................33 11.2 Non-Covered Infringement...........................................34 11.3 Penwest's Institution of Suit......................................34 11.4 Joint Suits........................................................34 11.5 Endo's Institution of Suit.........................................34 11.6 Abandonment of Suit................................................34 11.7 Patent Enforcement Litigation......................................35
Confidential ii {PAGE}
12. Escalation Procedures....................................................35 13. Arbitration..............................................................36 14. Miscellaneous............................................................37
EXHIBITS --------
Definitions Exhibit......................................................... 40
Exhibit 1.17 - Trademarks................................................... 52
Exhibit 1.28 - Accounting and Attribution Standards and Principals.......... 53
Exhibit 1.32 - Penwest Patents.............................................. 56
Exhibit 6.1 - Certain Jointly Filed Provisional Patent Applications......... 58
Confidential iii {PAGE}
AMENDED AND RESTATED
STRATEGIC ALLIANCE AGREEMENT
THIS AGREEMENT is entered into as of the 2nd day of April, 2002 (the "Restatement Date"), by and between Penwest Pharmaceuticals Co. ("Penwest"), a Washington corporation with its principal place of business at 2981 Route 22, Patterson, New York 12563, and Endo Pharmaceuticals Inc., a Delaware corporation with its principal place of business at 100 Painters Drive, Chadds Ford, Pennsylvania 19317 ("Endo").
WHEREAS, Penwest and Endo are party to that certain Strategic Alliance Agreement, dated as of September 17, 1997 (the "Old Agreement");
WHEREAS, in light of changes that have occurred at both Penwest and Endo since the execution of the Old Agreement, Penwest and Endo now wish to amend and restate the Old Agreement in its entirety;
WHEREAS, Penwest has developed an extended-release agent covered by one or more patents, patent applications, know-how and other proprietary technology, which agent Penwest markets under the name and mark "TIMERx(R)" ("TIMERx");
WHEREAS, Endo manufactures and markets the product marketed under the name "Numorphan(R)", having as an active drug substance oxymorphone HCl ("Oxymorphone") and has developed know-how and other proprietary technology with respect thereto;
WHEREAS, the parties, pursuant to the Old Agreement, have co-developed a product combining Oxymorphone and TIMERx, which product is a solid-dosage extended-release pharmaceutical for oral administration in humans in one or more dosage strengths and which product is referred to by the parties as "EN 3202";
WHEREAS, the parties desire to provide for the further development and commercialization of EN 3202 as provided herein; and
WHEREAS, Endo desires to contract for a supply of TIMERx for use in the manufacture of EN 3202, and Penwest is willing to supply the same provided that Endo agrees to obtain all of its and its Affiliates' and sublicensees' requirements of TIMERx from Penwest as provided herein;
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
1. DEFINITIONS. Certain terms used herein are defined in Sections 1.1 through 1.44 of the Definitions Exhibit attached hereto and incorporated herein by this reference.
Confidential 1 {PAGE}
2. [INTENTIONALLY OMITTED.]
3. CERTIFICATION PERIOD(S).
3.1 Covenants. Each of Penwest and Endo will exert its Best Commercial Efforts: (i) to perform the respective Certification Tasks allotted to it; (ii) to do so in accordance with the applicable Certification Budget; and (iii) to assist and to cooperate as requested with the other party's Best Commercial Efforts to do the same as to its own Certification Tasks.
3.2 Communication & Access. Each party will, promptly and throughout the term of this Agreement, provide to the other party all necessary or useful information in or coming into its possession or reasonably available to it to support the achievement of the Certification Tasks. Notwithstanding anything else to the contrary contained herein, nothing shall require either party to disclose confidential information for which such party has an obligation of confidentiality to a third party, but each party will exert its Best Commercial Efforts to bring to the attention of the Alliance Committee any such third party restrictions as may be relevant to its role hereunder.
3.3 Reports. Each Project Contact will be available throughout each Certification Period to answer any reasonable questions from the other party's Project Contact, as appropriate.
3.4 Supply. During each Certification Period in which it is participating, Endo shall provide Oxymorphone and related materials reasonably required to support the applicable Certification Tasks, and Penwest shall provide all Formulated TIMERx reasonably required therefor, all as shall be more fully described in the applicable Certification Tasks adopted by Committee Action. The costs of such materials will be treated as among the parties' respective expenditures pursuant to the applicable Certification Budget, using for this purpose the Formulated TIMERx Price as to the TIMERx and the Oxymorphone Price as to the Oxymorphone. Where, as permitted hereunder, a party is not participating in a Certification Period, it will sell such materials to the participating party pursuant to Section 6.8.4 hereof or Article 7 hereof, as applicable, and the price paid therefor shall be treated as part of the buyer's expenditures pursuant to the applicable Certification Budget.
3.5 U.S. Certification Budget; Election Not to Continue Participation. The parties hereby agree that the Alliance Committee, by Committee Action, shall on an annual basis approve the U.S. Certification Budget for the next twelve-month period. The parties hereby further agree that each party will share equally the total costs of each entire Certification Budget for the U.S. Certification Period regardless of which party is allocated one or more of the relevant Certification Tasks, subject to Section 5.5 hereof. If at any time, one party but not the other
Confidential 2 {PAGE}
desires to spend sums or devote resources not covered by a particular U.S. Certification Budget to complete Certification Tasks, then, upon such party giving notice to the other party under Section 5.5 hereof, the following shall apply (in addition to the provisions of Section 5.5 hereof):
3.5.1 The party that does not participate further in such U.S. Certification Period shall not be required to contribute to the reconciliations for the costs of such Certification Period under Section 3.7 hereof. Rather, a Certification Excess shall be established with respect to the Product in the U.S., which shall equal the sums such party would have paid under Section 3.7 hereof for such costs, had it fully participated in such Certification Period, but did not pay due to its election under this Section.
3.5.2 If Endo is the party electing not to participate further in such U.S. Certification Period, then Section 6.8 hereof shall apply and the other provisions of this Agreement shall remain in effect in accordance with their terms and the terms of Section 6.8; PROVIDED, HOWEVER, THAT, if a Certification Excess exists pursuant to Section 3.5.1 hereof (where Endo is the non-participating party), Penwest shall pay Endo proportionately less than the Applicable Percentage of the relevant Net Realization from the Product in the U.S., until Penwest has thereby recouped the amount of such Certification Excess. (That is, for example, if the total resources devoted by both Endo and Penwest to such Certification Period is [**] in this example, and Penwest bore [**] and Endo bore [**] of that total prior to Endo's making its election not to participate further, and if the Applicable Percentage is 50%, then Penwest would pay Endo [**] of the Net Realization from the Product in the U.S. until Penwest had thereby recouped the [**] total Certification Excess, which would occur in this example when the total of such Net Realization reaches [**].)
3.5.3 If Penwest is the party electing not to participate further in such U.S. Certification Period, then Section 6.7 shall apply and the other provisions of this Agreement shall remain in effect in accordance with their terms and the terms of Section 6.7; PROVIDED, HOWEVER, THAT, if a Certification Excess exists pursuant to Section 3.5.1 hereof (where Penwest is the non-participating party), Endo shall pay Penwest proportionately less than the Applicable Percentage of the relevant Net Realization from the Product in the U.S., until Endo has thereby recouped the amount of such Certification Excess. (That is, for example, if the total resources devoted by both Endo and Penwest to such Certification Period is [**] in this example, and Endo bore [**] and Penwest bore [**] of that total prior to Penwest's making its
Confidential 3 {PAGE}
election not to participate further, and if the
321016
|
Penwest Pharma
As referenced in this Strategic Alliance Agreement [Amended and Restated]:
PENWEST PHARMACEUTICALS CO – AGMNT
{TEXT}
{PAGE}
Exhibit 10.1
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
AMENDED AND RESTATED
STRATEGIC ALLIANCE AGREEMENT
BY AND BETWEEN
PENWEST PHARMACEUTICALS CO .
AND
ENDO PHARMACEUTICALS INC.
DATED AS OF APRIL 2, 2002
CONFIDENTIAL
{PAGE}
TABLE OF CONTENTS
1. Definitions...............................................................1
2. [INTENTIONALLY OMITTED.]..................................................2
3. Certification Period(s)...................................................2
3.1 _____________
Penwest Pharmaceuticals Co – Applications......... 58
Confidential iii
{PAGE}
AMENDED AND RESTATED
STRATEGIC ALLIANCE AGREEMENT
THIS AGREEMENT is entered into as of the 2nd day of April, 2002 (the
"Restatement Date"), by and between Penwest Pharmaceuticals Co . ("Penwest"), a
Washington corporation with its principal place of business at 2981 Route 22,
Patterson, New York 12563, and Endo Pharmaceuticals Inc., a Delaware corporation
with its principal place _____________
PENWEST PHARMACEUTICALS CO – 38
{PAGE}
IN WITNESS WHEREOF, the parties hereto have caused their duly
authorized officers to execute and acknowledge this Agreement as of the date
first written above.
ENDO PHARMACEUTICALS INC. PENWEST PHARMACEUTICALS CO .
By: /s/Carol A. Ammon By: /s/Tod R. Hamachek
----------------------------- ------------------------------------
Its: Chairman & CEO Its: Chairman & CEO
----------------------------- ------------------------------------
Address: Address:
100 Painters Drive 2981 Route 22
Chadds Ford, PA 19317 Patterson, _____________
Penwest Pharmaceuticals Co – in conjunction with Penwest's packaging and
promotion of the Product hereunder, pursuant to Section 8
hereof.
1.18 "ESCALATION OFFICER" shall mean the Chairman and Chief
Executive Officer of Penwest Pharmaceuticals Co . (currently
Tod Hamachek), and the Chief Executive Officer of Endo
(currently Carol Ammon), and the persons holding such
positions from time to time.
1.19 "ESCALATION PROCEDURE" shall mean _____________
dt 1318149
;
Hale and Dorr
As referenced in this Strategic Alliance Agreement [Amended and Restated]:
Hale and Dorr – 558-9682 FAX: (845) 878-3498
Attn: Carol A. Ammon Attn: Tod R. Hamachek
cc: Steven D. Singer, Esq.
cc: Caroline B. Manogue Hale and Dorr LLP
FAX: (610) 558-9684 60 State Street
Boston, Massachusetts 02109
FAX: (617) 526-5000
Confidential 39
{PAGE}
DEFINITIONS EXHIBIT
1. DEFINITIONS.
_____________
dt 639427
;
| Endo Pharmaceuticals Inc.
|
Preview
Full Doc
 | 2001 |
Marketing Alliance Agreement
Marketing Alliance Agreement (161K)
Doc #359680: Click preview link for longer preview.
MARKETING ALLIANCE AGREEMENT
MARKETING ALLIANCE AGREEMENT dated as of March 20, 2001 among CANADIAN IMPERIAL BANK OF COMMERCE, a bank formed under the laws of Canada (the "Bank"), and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation ("NDPS"), GLOBAL PAYMENTS CANADA INC. an Ontario corporation ("GPI CANADA") and GLOBAL PAYMENTS INC. a Georgia corporation ("GLOBAL PAYMENTS") as the guarantor of NDPS' and GPI Canada's obligations hereunder, as described on the last page of this Agreement.
WHEREAS, the Bank and NDPS (and National Data Corporation and Global Payments as the guarantors of NDPS' obligations) entered into an Asset Purchase Agreement dated November 9, 2000 (the "ASSET PURCHASE AGREEMENT"), pursuant to which the Bank agreed to sell to NDPS the Assets Sold (as defined therein);
WHEREAS, the parties have each agreed to undertake or cause to be undertaken certain activities with respect to the Merchant Business;
WHEREAS, it was a condition to the consummation of the transactions provided for in the Asset Purchase Agreement that the Bank and NDPS enter into this Marketing Alliance Agreement;
NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants contained herein, the Bank and NDPS agree as follows:
SECTION 1. DEFINITIONS AND INTERPRETATION
SECTION 1.1 CERTAIN DEFINED TERMS. For purposes of this Agreement, the following terms shall have the following meanings:
"ACCOUNT FEES" has the meaning set forth in Section 5.2.
"ADVISORS" means, with respect to a Person, the Person's employees, agents, professional advisors and consultants and "ADVISOR" means any one of them.
"AFFILIATES" means, with respect to the Person specified, a Person that Controls or is Controlled by, or is under common Control with, the Person specified.
"AGGREGATE TRANSACTION VOLUME" has the meaning set forth in Section 8.3(e).
"AMICUS" has the meaning set forth in Section 8.3(b).
"ARBITRATION" has the meaning set forth in Section 22.5.
"ARBITRATION ACT" has the meaning set forth in Section 22.5.
"ASSET PURCHASE AGREEMENT" has the meaning set forth in the Recitals.
1 {PAGE}
"ASSIGNED MERCHANT AGREEMENTS" means the Existing Merchant Agreements (but not the Excluded Merchant Agreements).
"ASSOCIATION RULES" means the rules and regulations established from time to time by a Credit Card Association or Network Organization.
"BANK DATA" means all data and information, including, but not limited to, personal information, account balance information, facts, records, business data tapes and documents, relating to the Bank's businesses (other than the Merchant Business or information which has otherwise been disclosed by a Merchant or a customer to NDPS and/or GPI Canada directly or is available in the public domain).
"BANK DEFAULT" has the meaning set forth in Section 14.2.
"BANK MARKS" means the Bank's trade name and trade-marks specifically identified in the Trademark Licence Agreement.
"BANK SERVICE LOCATION" means any location where the Bank performs Bank Services.
"BANK SERVICES" means the services to be provided by, and all other obligations of, the Bank expressly provided for in this Agreement in fulfilment of obligations under the Merchant Agreements, including the Transition Services for so long as, and to the extent that, they are provided under the Transition Agreement.
"BANK'S U.S. ICAS/BINS" has the meaning set forth in Section 8.3(b).
"BIN" means a Bank Identification Number used in connection with Credit Card Transactions, as described in greater detail in the applicable Association Rules.
"BIN REPORTING" has the meaning set forth in Section 8.2.
"BUSINESS DAY" means any day excluding Saturday, Sunday and any day on which banking institutions located in Toronto, Ontario, St. Louis, Missouri or Atlanta, Georgia are authorized by law or other governmental action to be closed.
"BUSINESS RECOVERY PLANS" means, as the case may be, NDPS' and/or GPI Canada's business recovery procedures with respect to the Merchant Business to be implemented by NDPS and GPI Canada pursuant to the conditions imposed by the Office of the Superintendent of Financial Institutions in its conditional order permitting NDPS to process data relating to the Merchant Business from a location outside Canada, and under the Transition Agreement, such procedures may be updated and modified from time to time in accordance with the terms of this Agreement, and the Bank's business recovery procedures with respect to the Bank Services, as such procedures may be modified from time to time in accordance with the terms of this Agreement.
2 {PAGE}
"CANADIAN FINANCIAL INSTITUTION" has the meaning set forth in the Asset Purchase Agreement.
"CARD TRANSACTIONS" means Credit Card Transactions and Debit Card Transactions.
"CHAIR" has the meaning ascribed thereto in Section 22.5.
"CHARGEBACK" has the meaning, with respect to VISA, specified in the VISA Rules and, with respect to any other Credit Card Association or Network Organization, has the meaning given to the equivalent term under the applicable Association Rules.
"CIBC SYSTEM" has the meaning set forth in Section 10.5.
"CLEARING SYSTEM RULES" means, for a Clearing System, the rules and regulations established from time to time relating to the use and operation of the Clearing System.
"CLEARING SYSTEM" means the relevant payment system, such as the Canadian Payments Association, used to effect payments for Card Transactions.
"CLIENT RELATIONS REPRESENTATIVE" has the meaning set forth in Section 15.1.
"COMMERCIALLY REASONABLE EFFORTS" means the efforts that a prudent person who desires to complete a transaction or other action would use in similar circumstances to ensure that a closing or other result occurs as expeditiously as possible without the necessity of assuming any material obligations or paying any material amounts to an unrelated third party.
"CONTROL" exists when a Person owns beneficially, directly or indirectly, more than 50% of another Person's outstanding voting securities or where a Person has the ability to elect a majority of the directors of another Person;
"CREDIT CARD" means a credit card or Off-Line Debit Card bearing the symbol of a Credit Card Association which is accepted by a Merchant pursuant to the terms of a Merchant Agreement, and in respect of which Credit Card Transactions are cleared and settled through the Credit Card Interchange System.
"CREDIT CARD ASSOCIATIONS" means VISA U.S.A., Inc., VISA Canada Inc., the Canadian MasterCard entity, if any, MasterCard USA, Inc., Visa International, Inc., MasterCard International, Inc. or any other association that the parties may agree upon from time to time and any successor organization or association of any of them.
"CREDIT CARD CLEARING DATE" means the date the Credit Card Association receives the information relating to a Card Transaction from NDPS or its Merchant Accounting Processor.
3 {PAGE}
"CREDIT CARD INTERCHANGE SYSTEM" means a system of clearing and settling Credit Card Transactions established by a Credit Card Association.
"CREDIT CARD TRANSACTION" means an electronic or documentary transaction
359680
|
Global Payments
As referenced in this Marketing Alliance Agreement:
GLOBAL PAYMENTS
INC – bank formed under the laws of Canada (the "Bank"),
and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation ("NDPS"), GLOBAL
PAYMENTS CANADA INC. an Ontario corporation ("GPI CANADA") and GLOBAL PAYMENTS
INC . a Georgia corporation ("GLOBAL PAYMENTS") as the guarantor of NDPS' and GPI
Canada's obligations hereunder, as described on the last page of this Agreement.
WHEREAS, the Bank and _____________
Global Payments Inc – the Committee shall be the remaining
director if any, of
5
{PAGE}
Global Payments, and an officer or officers of the Bank designated by the Bank)
and two directors of Global Payments Inc . designated by NDPS.
"KEY ACCOUNTS" has the meaning set forth in Section 2.7.
"KEY ACCOUNT NOTICE" has the meaning set forth in Section 2.7.
"LAWS" means all _____________
Global Payments Inc – Bay Street, 28th Floor
Commerce Court West
Toronto, Ontario M5L 1A9
47
{PAGE}
Attn: Managing Partner
Facsimile: (416) 863-2653
(b) If to NDPS, Global Payments
or GPI Canada to: Global Payments Inc .
#4 Corporate Square
Atlanta, Georgia 30329-2010
Attn.: Office of the Corporate Secretary
Facsimile: (404) 728-2990
The persons or addresses to which mailings or deliveries shall be made _____________
GLOBAL PAYMENTS INC – By: /s/ Suellyn P. Tornay
---------------------------------------
Name: Suellyn P. Tornay
Title: General Counsel
The obligations of National Data Payment Systems, Inc. and Global Payments
Canada Inc. hereunder are hereby guaranteed by GLOBAL PAYMENTS INC .
GLOBAL PAYMENTS INC.
By: /s/ Suellyn P. Tornay
---------------------------------------
Name: Suellyn P. Tornay
Title: General Counsel
51
{PAGE}
SCHEDULE 2.5
NEW MERCHANT AGREEMENTS
To be mutually agreed upon by _____________
GLOBAL PAYMENTS INC – P. Tornay
---------------------------------------
Name: Suellyn P. Tornay
Title: General Counsel
The obligations of National Data Payment Systems, Inc. and Global Payments
Canada Inc. hereunder are hereby guaranteed by GLOBAL PAYMENTS INC.
GLOBAL PAYMENTS INC .
By: /s/ Suellyn P. Tornay
---------------------------------------
Name: Suellyn P. Tornay
Title: General Counsel
51
{PAGE}
SCHEDULE 2.5
NEW MERCHANT AGREEMENTS
To be mutually agreed upon by the parties.
52
{ _____________
dt 1536492
;
|
CIBC
As referenced in this Marketing Alliance Agreement:
CANADIAN
IMPERIAL BANK OF COMMERCE, – txt
{DESCRIPTION}MARKETING ALLIANCE AGREEMENT
{TEXT}
{PAGE}
Exhibit 10.3
MARKETING ALLIANCE AGREEMENT
MARKETING ALLIANCE AGREEMENT dated as of March 20, 2001 among CANADIAN
IMPERIAL BANK OF COMMERCE, a bank formed under the laws of Canada (the "Bank"),
and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation ("NDPS"), GLOBAL
_____________
Canadian Imperial Bank of Commerce
– SECTION 23.2 NOTICES. All notices required hereunder shall be delivered to the
following names and addresses:
(a) If to the Bank, to: Canadian Imperial Bank of Commerce
c/o CIBC World Markets Inc.
161 Bay Street, BCE Place,7th Floor
Toronto, Ontario M5J 2J8
Attn: Executive Vice President, Card _____________
Canadian Imperial Bank of Commerce
– Toronto, Ontario M5J 2J8
Attn: Executive Vice President, Card Products,
Collections and Merchant Card Services
Facsimile: (416) 784-6868
with a copy to:
Canadian Imperial Bank of Commerce
Legal and Compliance Division
199 Bay Street, 15th Floor
Commerce Court West
Toronto, Ontario M5L 1A2
Attn: General Counsel
Facsimile: (416) 304- _____________
CANADIAN IMPERIAL BANK OF COMMERCE
– parties hereto have caused this agreement to be executed
by their respective officers thereunto duly authorized, as of the date first
above written.
CANADIAN IMPERIAL BANK OF COMMERCE
By: /s/ Christine Croucher
---------------------------------------
Name: Christine Croucher
Title:
By: /s/ David A. Caldwell
---------------------------------------
Name: David A. Caldwell
Title:
NATIONAL DATA PAYMENT SYSTEMS, _____________
dt 719062
|
Preview
Full Doc
 | 2001 |
Marketing Alliance Agreement
Marketing Alliance Agreement (163K)
Doc #359687: Click preview link for longer preview.
MARKETING ALLIANCE AGREEMENT
MARKETING ALLIANCE AGREEMENT dated as of March 20, 2001 among CANADIAN IMPERIAL BANK OF COMMERCE, a bank formed under the laws of Canada (the "Bank"), and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation ("NDPS"), GLOBAL PAYMENTS CANADA INC. an Ontario corporation ("GPI Canada") and GLOBAL PAYMENTS INC. a Georgia corporation ("Global Payments") as the guarantor of NDPS' and GPI Canada's obligations hereunder, as described on the last page of this Agreement.
WHEREAS, the Bank and NDPS (and National Data Corporation and Global Payments as the guarantors of NDPS' obligations) entered into an Asset Purchase Agreement dated November 9, 2000 (the "Asset Purchase Agreement"), pursuant to which the Bank agreed to sell to NDPS the Assets Sold (as defined therein);
WHEREAS, the parties have each agreed to undertake or cause to be undertaken certain activities with respect to the Merchant Business;
WHEREAS, it was a condition to the consummation of the transactions provided for in the Asset Purchase Agreement that the Bank and NDPS enter into this Marketing Alliance Agreement;
NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants contained herein, the Bank and NDPS agree as follows:
SECTION 1. DEFINITIONS AND INTREPRETATION
SECTION 1.1 Certain Defined Terms. For purposes of this Agreement, the following terms shall have the following meanings:
"Account Fees" has the meaning set forth in Section 5.2.
"Advisors" means, with respect to a Person, the Person's employees, agents, professional advisors and consultants and "Advisor" means any one of them.
"Affiliates" means, with respect to the Person specified, a Person that Controls or is Controlled by, or is under common Control with, the Person specified.
"Aggregate Transaction Volume" has the meaning set forth in Section 8.3(e).
"Amicus" has the meaning set forth in Section 8.3(b).
"Arbitration" has the meaning set forth in Section 22.5.
"Arbitration Act" has the meaning set forth in Section 22.5.
{PAGE}
"Asset Purchase Agreement" has the meaning set forth in the Recitals.
"Assigned Merchant Agreements" means the Existing Merchant Agreements (but not the Excluded Merchant Agreements).
"Association Rules" means the rules and regulations established from time to time by a Credit Card Association or Network Organization.
"Bank Data" means all data and information, including, but not limited to, personal information, account balance information, facts, records, business data tapes and documents, relating to the Bank's businesses (other than the Merchant Business or information which has otherwise been disclosed by a Merchant or a customer to NDPS and/or GPI Canada directly or is available in the public domain).
"Bank Default" has the meaning set forth in Section 14.2.
"Bank Marks" means the Bank's trade name and trade-marks specifically identified in the Trademark Licence Agreement.
"Bank Service Location" means any location where the Bank performs Bank Services.
"Bank Services" means the services to be provided by, and all other obligations of, the Bank expressly provided for in this Agreement in fulfilment of obligations under the Merchant Agreements, including the Transition Services for so long as, and to the extent that, they are provided under the Transition Agreement.
"Bank's U.S. ICAs/BINs" has the meaning set forth in Section 8.3(b).
"BIN" means a Bank Identification Number used in connection with Credit Card Transactions, as described in greater detail in the applicable Association Rules.
"BIN Reporting" has the meaning set forth in Section 8.2.
"Business Day" means any day excluding Saturday, Sunday and any day on which banking institutions located in Toronto, Ontario, St. Louis, Missouri or Atlanta, Georgia are authorized by law or other governmental action to be closed.
"Business Recovery Plans" means, as the case may be, NDPS' and/or GPI Canada's business recovery procedures with respect to the Merchant Business to be implemented by NDPS and GPI Canada pursuant to the conditions imposed by the Office of the Superintendent of Financial Institutions in its conditional order permitting NDPS to process data relating to the Merchant
-2-
{PAGE}
Business from a location outside Canada, and under the Transition Agreement, such procedures may be updated and modified from time to time in accordance with the terms of this Agreement, and the Bank's business recovery procedures with respect to the Bank Services, as such procedures may be modified from time to time in accordance with the terms of this Agreement.
"Canadian Financial Institution" has the meaning set forth in the Asset Purchase Agreement.
"Card Transactions" means Credit Card Transactions and Debit Card Transactions.
"Chair" has the meaning ascribed thereto in Section 22.5.
"Chargeback" has the meaning, with respect to VISA, specified in the VISA Rules and, with respect to any other Credit Card Association or Network Organization, has the meaning given to the equivalent term under the applicable Association Rules.
"CIBC System" has the meaning set forth in Section 10.5.
"Clearing System Rules" means, for a Clearing System, the rules and regulations established from time to time relating to the use and operation of the Clearing System.
"Clearing System" means the relevant payment system, such as the Canadian Payments Association, used to effect payments for Card Transactions.
"Client Relations Representative" has the meaning set forth in Section 15.1.
"Commercially Reasonable Efforts" means the efforts that a prudent person who desires to complete a transaction or other action would use in similar circumstances to ensure that a closing or other result occurs as expeditiously as possible without the necessity of assuming any material obligations or paying any material amounts to an unrelated third party.
"Control" exists when a Person owns beneficially, directly or indirectly, more than 50% of another Person's outstanding voting securities or where a Person has the ability to elect a majority of the directors of another Person;
"Credit Card" means a credit card or Off-Line Debit Card bearing the symbol of a Credit Card Association which is accepted by a Merchant pursuant to the terms of a Merchant Agreement, and in respect of which Credit Card Transactions are cleared and settled through the Credit Card Interchange System.
-3-
{PAGE}
"Credit Card Associations" means VISA U.S.A., Inc., VISA Canada Inc., the Canadian MasterCard entity, if any, MasterCard USA, Inc., Visa International, Inc., MasterCard International, Inc. or any other association that the parties may agree upon from time to time and any successor organization or association of any of them.
"Credit Card Clearing Date" means the date the Credit Card Association receives the information relating to a Card Transaction from NDPS or its Merchant Accounting Processor.
"Credit Card Interchange System" means a system of clearing and settling Credit Card Transactions established by a Credit Card Association.
"Credit Card Transaction" means an electronic or documentary transaction
359687
|
Global Payments
As referenced in this Marketing Alliance Agreement:
GLOBAL PAYMENTS INC – bank formed under the laws of Canada (the
"Bank"), and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation
("NDPS"), GLOBAL PAYMENTS CANADA INC. an Ontario corporation ("GPI Canada")
and GLOBAL PAYMENTS INC . a Georgia corporation ("Global Payments") as the
guarantor of NDPS' and GPI Canada's obligations hereunder, as described on
the last page of this Agreement.
WHEREAS, the Bank and _____________
Global Payments Inc – Bank on the Committee shall be the
remaining director if any, of Global Payments, and an officer or officers of
the Bank designated by the Bank) and two directors of Global Payments Inc .
designated by NDPS.
"Key Accounts" has the meaning set forth in Section 2.7.
"Key Account Notice" has the meaning set forth in Section 2.7.
"Laws" means all _____________
Global Payments Inc – LLP
199 Bay Street, 28th Floor
Commerce Court West
Toronto, Ontario M5L 1A9
Attn: Managing Partner
Facsimile: (416) 863-2653
(b) If to NDPS, Global Payments
or GPI Canada to:
Global Payments Inc .
#4 Corporate Square
Atlanta, Georgia 30329-2010
Attn.: Office of the Corporate Secretary
Facsimile: (404) 728-2990
The persons or addresses to which mailings or deliveries shall be made _____________
GLOBAL PAYMENTS INC – By: /s/ Suellyn P. Tornay
--------------------------------------
Name: Suellyn P. Tornay
Title: General Counsel
The obligations of National Data Payment Systems, Inc. and Global Payments
Canada Inc. hereunder are hereby guaranteed by GLOBAL PAYMENTS INC .
GLOBAL PAYMENTS INC.
By: /s/ Suellyn P. Tornay
--------------------------------------
Name: Suellyn P. Tornay
Title: General Counsel
-56-
{PAGE}
SCHEDULE 2.5
NEW MERCHANT AGREEMENTS
To be mutually agreed upon by _____________
GLOBAL PAYMENTS INC – P. Tornay
--------------------------------------
Name: Suellyn P. Tornay
Title: General Counsel
The obligations of National Data Payment Systems, Inc. and Global Payments
Canada Inc. hereunder are hereby guaranteed by GLOBAL PAYMENTS INC.
GLOBAL PAYMENTS INC .
By: /s/ Suellyn P. Tornay
--------------------------------------
Name: Suellyn P. Tornay
Title: General Counsel
-56-
{PAGE}
SCHEDULE 2.5
NEW MERCHANT AGREEMENTS
To be mutually agreed upon by the parties.
-57-
{ _____________
dt 1536496
;
|
CIBC
As referenced in this Marketing Alliance Agreement:
CANADIAN
IMPERIAL BANK OF COMMERCE, – SEQUENCE}2
{FILENAME}0002.txt
{TEXT}
Exhibit 3
Conformed Copy
MARKETING ALLIANCE AGREEMENT
MARKETING ALLIANCE AGREEMENT dated as of March 20, 2001 among CANADIAN
IMPERIAL BANK OF COMMERCE, a bank formed under the laws of Canada (the
"Bank"), and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation
("NDPS"), GLOBAL _____________
Canadian Imperial Bank of Commerce
– SECTION 23.2 Notices. All notices required hereunder shall be delivered to
the following names and addresses:
(a) If to the Bank, to:
Canadian Imperial Bank of Commerce
c/o CIBC World Markets Inc.
161 Bay Street,
BCE Place,7th Floor
Toronto, Ontario M5J 2J8
Attn: Executive Vice President, Card _____________
Canadian Imperial Bank of Commerce
– Toronto, Ontario M5J 2J8
Attn: Executive Vice President, Card Products,
Collections and Merchant Card Services
Facsimile: (416) 784-6868
with a copy to:
Canadian Imperial Bank of Commerce
Legal and Compliance Division
199 Bay Street, 15th Floor
Commerce Court West
Toronto, Ontario M5L 1A2
Attn: General Counsel
Facsimile: (416) 304- _____________
CANADIAN IMPERIAL BANK OF COMMERCE
– parties hereto have caused this agreement to be
executed by their respective officers thereunto duly authorized, as of the
date first above written.
CANADIAN IMPERIAL BANK OF COMMERCE
By: /s/ Christine Croucher
---------------------------------------
Name: Christine Croucher
Title: Executive Vice President
By: /s/ David A. Marshall
---------------------------------------
Name: David A. Marshall
Title: Vice _____________
dt 719068
|
Preview
Full Doc
 | 2000 |
Marketing Alliance Agreement
Marketing Alliance Agreement (157K)
Doc #359724: Click preview link for longer preview.
MARKETING ALLIANCE AGREEMENT ----------------------------
MARKETING ALLIANCE AGREEMENT dated as of ______________ among CANADIAN IMPERIAL BANK OF COMMERCE, a bank formed under the laws of Canada (the "Bank"), and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation ("NDPS") and Global Payments Inc. ("Global Payments") as the guarantor of NDPS' obligations hereunder, as described on the last page of this Agreement.
WHEREAS, the Bank and NDPS entered into an Asset Purchase Agreement dated _________________ (the "Asset Purchase Agreement"), pursuant to which the Bank agreed to sell to NDPS or an Affiliate of NDPS, the Assets Sold (as defined therein);
WHEREAS, the parties have each agreed to undertake or cause to be undertaken certain activities with respect to the Merchant Business;
WHEREAS, it was a condition to the consummation of the transactions provided for in the Asset Purchase Agreement that the Bank and NDPS enter into this Marketing Alliance Agreement;
NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants contained herein, the Bank and NDPS agree as follows:
SECTION 1. DEFINITIONS AND INTERPRETATION
SECTION 1.1 Certain Defined Terms. For purposes of this Agreement, the --------------------- following terms shall have the following meanings:
"Account Fees" has the meaning set forth in Section 5.2.
"Advisors" means, with respect to a Person, the Person's employees, agents, professional advisors and consultants and "Advisor" means any one of them.
"Affiliates" means, with respect to the Person specified, a Person that Controls or is Controlled by, or is under common Control with, the Person specified.
"Arbitration" has the meaning set forth in Section 22.5.
"Arbitration Act" has the meaning set forth in Section 22.5.
"Asset Purchase Agreement" has the meaning set forth in the Recitals.
"Assigned Merchant Agreements" means the Existing Merchant Agreements (but not the Excluded Merchant Agreements).
1 {PAGE}
"Association Rules" means the rules and regulations established from time to time by a Credit Card Association or Network Organization.
"Bank Data" means all data and information, including, but not limited to, personal information, account balance information, facts, records, business data tapes and documents, relating to the Bank's businesses (other than the Merchant Business or information which has otherwise been disclosed by a Merchant or a customer to NDPS directly or is available in the public domain).
"Bank Default" has the meaning set forth in Section 14.2.
"Bank Marks" means the Bank's trade name and trade-marks specifically identified in the Trademark Licence Agreement.
"Bank Service Location" means any location where the Bank performs Bank Services.
"Bank Services" means the services to be provided by, and all other obligations of, the Bank expressly provided for in this Agreement in fulfilment of obligations under the Merchant Agreements, including the Transition Services for so long as, and to the extent that, they are provided under the Transition Agreement.
"BIN" means a Bank Identification Number used in connection with Credit Card Transactions, as described in greater detail in the applicable Association Rules.
"BIN Reporting" has the meaning set forth in Section 8.2.
"Business Day" means any day excluding Saturday, Sunday and any day on which banking institutions located in Toronto, Ontario, St. Louis, Missouri or Atlanta, Georgia are authorized by law or other governmental action to be closed.
"Business Recovery Plans" means, as the case may be, NDPS' business recovery procedures with respect to the Merchant Business currently in the form attached hereto as Schedule 12.1, as updated and modified from time to time in ------------- accordance with the terms of this Agreement, and the Bank's business recovery procedures with respect to the Bank Services, as updated and modified from time to time in accordance with the terms of this Agreement.
"Canadian Financial Institution" has the meaning set forth in the Asset Purchase Agreement.
"Card Transactions" means Credit Card Transactions and Debit Card Transactions.
"Chair" has the meaning ascribed thereto in Section 22.5.
2 {PAGE}
"Chargeback" has the meaning, with respect to VISA, specified in the VISA Rules and, with respect to any other Credit Card Association or Network Organization, has the meaning given to the equivalent term under the applicable Association Rules.
"CIBC System" has the meaning set forth in Section 10.5.
"Clearing System Rules" means, for a Clearing System, the rules and regulations established from time to time relating to the use and operation of the Clearing System.
"Clearing System" means the relevant payment system, such as the Canadian Payments Association, used to effect payments for Card Transactions.
"Client Relations Representative" has the meaning set forth in Section 15.1.
"Commercially Reasonable Efforts" means the efforts that a prudent person who desires to complete a transaction or other action would use in similar circumstances to ensure that a closing or other result occurs as expeditiously as possible without the necessity of assuming any material obligations or paying any material amounts to an unrelated third party.
"Control" exists when a Person owns beneficially, directly or indirectly, more than 50% of another Person's outstanding voting securities or where a Person has the ability to elect a majority of the directors of another Person;
"Credit Card" means a credit card or Off-Line Debit Card bearing the symbol of a Credit Card Association which is accepted by a Merchant pursuant to the terms of a Merchant Agreement, and in respect of which Credit Card Transactions are cleared and settled through the Credit Card Interchange System.
"Credit Card Associations" means VISA U.S.A., Inc., VISA Canada Inc., the Canadian MasterCard entity, if any, MasterCard USA, Inc., Visa International, Inc., MasterCard International, Inc. or any other association that the parties may agree upon from time to time and any successor organization or association of any of them.
"Credit Card Clearing Date" means the date the Credit Card Association receives the information relating to a Card Transaction from NDPS or its Merchant Accounting Processor.
"Credit Card Interchange System" means a system of clearing and settling Credit Card Transactions established by a Credit Card Association.
"Credit Card Transaction" means an electronic or documentary transaction involving a Merchant pursuant to which the method of payment is by Credit Card.
3 {PAGE}
"Credit Card Transaction Records" means the electronic or documentary files relating to Credit Card Transactions.
"Credit Facility" has the meaning set forth in the Asset Purchase Agreement.
"Credit Loss" means a loss resulting from the failure by a Merchant to pay amounts owed by it under a Merchant Agreement, other than amounts owed by reason of a Chargeback.
"Debit Card" means an on-line debit card, bearing the symbol of a Network
359724
|
Global Payments
As referenced in this Marketing Alliance Agreement:
Global Payments Inc – of ______________ among CANADIAN
IMPERIAL BANK OF COMMERCE, a bank formed under the laws of Canada (the "Bank"),
and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation ("NDPS") and
Global Payments Inc . ("Global Payments") as the guarantor of NDPS' obligations
hereunder, as described on the last page of this Agreement.
WHEREAS, the Bank and NDPS entered into an Asset Purchase Agreement _____________
Global Payments Inc – Bank on the Committee shall be the remaining
director if any, of Global Payments, and an officer or officers of the Bank
designated by the Bank) and two directors of Global Payments Inc . designated by
NDPS.
"Key Accounts" has the meaning set forth in Section 2.7.
"Key Account Notice" has the meaning set forth in Section 2.7.
"Laws" means all _____________
Global Payments Inc – 863-2653
(b) If to NDPS to: National Data Payment Systems, Inc.
7240 Parkway Drive, Suite 400
Hanover, Maryland 21076
Attn: General Manager
Facsimile:
(c) If to Global
Payments to: Global Payments Inc .
#2 National Data Plaza
Atlanta, Georgia 30329-2010
Attn.: Office of the Corporate Secretary
Facsimile:
The persons or addresses to which mailings or deliveries shall be made may be
_____________
GLOBAL PAYMENTS INC – _______________________________________
Name:
Title:
NATIONAL DATA PAYMENT SYSTEMS, INC.
By:______________________________________
Name: Suellyn P. Tornay
Title: General Counsel
The obligations of National Data Payment Systems, Inc. hereunder are hereby
guaranteed by GLOBAL PAYMENTS INC .
GLOBAL PAYMENTS INC.
By:______________________________________
Name:
Title:
47
{PAGE}
{TABLE}
{CAPTION}
{S} {C} {C}
SECTION 1. DEFINITIONS AND INTERPRETATION............................................................. 1
SECTION 1.1 Certain Defined Terms...................................................................... 1
SECTION 1. _____________
GLOBAL PAYMENTS INC – NATIONAL DATA PAYMENT SYSTEMS, INC.
By:______________________________________
Name: Suellyn P. Tornay
Title: General Counsel
The obligations of National Data Payment Systems, Inc. hereunder are hereby
guaranteed by GLOBAL PAYMENTS INC.
GLOBAL PAYMENTS INC .
By:______________________________________
Name:
Title:
47
{PAGE}
{TABLE}
{CAPTION}
{S} {C} {C}
SECTION 1. DEFINITIONS AND INTERPRETATION............................................................. 1
SECTION 1.1 Certain Defined Terms...................................................................... 1
SECTION 1.2 Headings and _____________
dt 1536507
;
|
CIBC
As referenced in this Marketing Alliance Agreement:
CANADIAN
IMPERIAL BANK OF COMMERCE, – txt
{DESCRIPTION}FORM OF MARKETING ALLIANCE AGREEMENT
{TEXT}
{PAGE}
EXHIBIT 10.21
MARKETING ALLIANCE AGREEMENT
----------------------------
MARKETING ALLIANCE AGREEMENT dated as of ______________ among CANADIAN
IMPERIAL BANK OF COMMERCE, a bank formed under the laws of Canada (the "Bank"),
and NATIONAL DATA PAYMENT SYSTEMS, INC., a New York corporation ("NDPS") and
_____________
Canadian Imperial Bank of Commerce
– SECTION 23.2 Notices. All notices required hereunder shall be delivered to the
-------
following names and addresses:
(a) If to the Bank, to: Canadian Imperial Bank of Commerce
c/o CIBC World Markets Inc.
161 Bay Street,
43
{PAGE}
BCE Place,7th Floor
Toronto, Ontario M5J 2J8
Attn: Executive Vice _____________
Canadian Imperial Bank of Commerce
– Toronto, Ontario M5J 2J8
Attn: Executive Vice President, Card Products,
Collections and Merchant Card Services
Facsimile: (416) 784-6868
with a copy to:
Canadian Imperial Bank of Commerce
Legal and Compliance Division
199 Bay Street, 15th Floor
Commerce Court West
Toronto, Ontario M5L 1A2
Attn: General Counsel
Facsimile: (416) 304- _____________
CANADIAN IMPERIAL BANK OF COMMERCE
– parties hereto have caused this agreement to be executed
by their respective officers thereunto duly authorized, as of the date first
above written.
CANADIAN IMPERIAL BANK OF COMMERCE
By:_______________________________________
Name:
Title:
By:_______________________________________
Name:
Title:
NATIONAL DATA PAYMENT SYSTEMS, INC.
By:______________________________________
Name: Suellyn P. Tornay
Title: General Counsel
_____________
dt 719084
|
Preview
Full Doc
 | 2004 |
Strategic Alliance Agreement
Strategic Alliance Agreement (31K)
Doc #405748: Click preview link for longer preview.
Strategic Alliance Agreement
This Strategic Alliance Agreement is made this 8th day of October 2003,
by and between USA Technologies, Inc., a Pennsylvania corporation ("USA"), and
Conopco, Inc. dba Unilever Home & Personal Care North America, a New York
corporation ("Unilever").
Background
USA is a provider of an unattended laundry injection system known as
e-Suds, all as more fully described in Exhibit "A" hereto ("USA e-Suds System").
Unilever . . .
405748
|
USA Technologies
As referenced in this Strategic Alliance Agreement:
USA Technologies, Inc – 10.1
{SEQUENCE}3
{FILENAME}ex10_1.txt
{TEXT}
{PAGE}
Exhibit 10.1
Strategic Alliance Agreement
This Strategic Alliance Agreement is made this 8th day of October 2003,
by and between USA Technologies, Inc ., a Pennsylvania corporation ("USA"), and
Conopco, Inc. dba Unilever Home & Personal Care North America, a New York
corporation ("Unilever").
Background
USA is a provider of an unattended laundry injection _____________
USA Technologies, Inc – in
person or national overnight courier or sent by certified mail, postage prepaid,
return receipt requested, as follows, unless such address is changed by written
notice hereunder:
If to USA:
USA Technologies, Inc .
100 Deerfield Lane, Suite 140
Malvern, Pennsylvania 19355
Attn. President
If to Unilever:
Unilever Home & Personal Care North America
33 Benedict Place
Greenwich, Connecticut 06385
Attn. President
With a _____________
USA TECHNOLOGIES, INC – a writing signed on behalf of the
parties hereto.
{PAGE}
IN WITNESS WHEREOF, the parties hereto have executed and delivered this
Agreement on the day and year first above written.
USA TECHNOLOGIES, INC . CONOPCO, INC.
dba Unilever Home & Personal Care
North America
By: /s/ Stephen Herbert By: /s/ Bob Shipley
-------------------- --------------------
Name: Stephen Herbert Name: Bob Shipley
Title: President Title:General Manager, Laundry
_____________
dt 1538199
| |